<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Brain Behav</journal-id>
<journal-id journal-id-type="iso-abbrev">Brain Behav</journal-id>
<journal-id journal-id-type="doi">10.1002/(ISSN)2157-9032</journal-id>
<journal-id journal-id-type="publisher-id">BRB3</journal-id>
<journal-title-group>
<journal-title>Brain and Behavior</journal-title>
</journal-title-group>
<issn pub-type="epub">2162-3279</issn>
<publisher>
<publisher-name>John Wiley and Sons Inc.</publisher-name>
<publisher-loc>Hoboken</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29934975</article-id>
<article-id pub-id-type="pmc">6085908</article-id>
<article-id pub-id-type="doi">10.1002/brb3.978</article-id>
<article-id pub-id-type="publisher-id">BRB3978</article-id>
<article-categories>
<subj-group subj-group-type="overline">
<subject>Review</subject>
</subj-group>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Autism throughout genetics: Perusal of the implication of ion channels</article-title>
<alt-title alt-title-type="left-running-head">DAGHSNI et al.</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" id="brb3978-cr-0001">
<name>
<surname>Daghsni</surname>
<given-names>Marwa</given-names>
</name>
<contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-7763-2933</contrib-id>
<xref ref-type="aff" rid="brb3978-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb3978-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="brb3978-note-1002">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb3978-cr-0002">
<name>
<surname>Rima</surname>
<given-names>Mohamad</given-names>
</name>
<xref ref-type="aff" rid="brb3978-aff-0003">
<sup>3</sup>
</xref>
<xref ref-type="author-notes" rid="brb3978-note-1002">
<sup>†</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb3978-cr-0003">
<name>
<surname>Fajloun</surname>
<given-names>Ziad</given-names>
</name>
<xref ref-type="aff" rid="brb3978-aff-0004">
<sup>4</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb3978-cr-0004">
<name>
<surname>Ronjat</surname>
<given-names>Michel</given-names>
</name>
<xref ref-type="aff" rid="brb3978-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb3978-aff-0005">
<sup>5</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb3978-cr-0005">
<name>
<surname>Brusés</surname>
<given-names>Juan L.</given-names>
</name>
<xref ref-type="aff" rid="brb3978-aff-0006">
<sup>6</sup>
</xref>
</contrib>
<contrib contrib-type="author" id="brb3978-cr-0006">
<name>
<surname>M'rad</surname>
<given-names>Ridha</given-names>
</name>
<xref ref-type="aff" rid="brb3978-aff-0002">
<sup>2</sup>
</xref>
<xref ref-type="aff" rid="brb3978-aff-0007">
<sup>7</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes" id="brb3978-cr-0007">
<name>
<surname>De Waard</surname>
<given-names>Michel</given-names>
</name>
<address>
<email>michel.dewaard@univ-nantes.fr</email>
</address>
<xref ref-type="aff" rid="brb3978-aff-0001">
<sup>1</sup>
</xref>
<xref ref-type="aff" rid="brb3978-aff-0005">
<sup>5</sup>
</xref>
</contrib>
</contrib-group>
<aff id="brb3978-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">L'institut du Thorax</named-content>
<named-content content-type="organisation-division">INSERM UMR1087/CNRS UMR6291</named-content>
<institution>Université de Nantes</institution>
<named-content content-type="city">Nantes</named-content>
<country country="FR">France</country>
</aff>
<aff id="brb3978-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Université de Tunis El Manar, Faculté de Médecine de Tunis</named-content>
<institution>LR99ES10 Laboratoire de Génétique Humaine</institution>
<named-content content-type="city">1007, Tunis</named-content>
<country>Tunisie</country>
</aff>
<aff id="brb3978-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Neuroscience</named-content>
<named-content content-type="organisation-division">Institute of Biology Paris‐Seine</named-content>
<named-content content-type="organisation-division">CNRS UMR 8246</named-content>
<named-content content-type="organisation-division">INSERM U1130</named-content>
<institution>Sorbonne Universités</institution>
<named-content content-type="city">Paris</named-content>
<country country="FR">France</country>
</aff>
<aff id="brb3978-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Azm Center for Research in Biotechnology and Its Application</named-content>
<institution>Lebanese University</institution>
<named-content content-type="city">Tripoli</named-content>
<country country="LB">Lebanon</country>
</aff>
<aff id="brb3978-aff-0005">
<label><sup>5</sup></label>
<institution>LabEx Ion Channels Science and Therapeutics</institution>
<named-content content-type="city">Nice</named-content>
<country country="FR">France</country>
</aff>
<aff id="brb3978-aff-0006">
<label><sup>6</sup></label>
<named-content content-type="organisation-division">Department of Natural Sciences</named-content>
<institution>Mercy College</institution>
<named-content content-type="city">Dobbs Ferry</named-content>
<named-content content-type="country-part">NY</named-content>
<country country="US">USA</country>
</aff>
<aff id="brb3978-aff-0007">
<label><sup>7</sup></label>
<named-content content-type="organisation-division">Service des Maladies Congénitales et Héréditaires</named-content>
<institution>Hôpital Charles Nicolle</institution>
<named-content content-type="city">Tunis</named-content>
<country>Tunisie</country>
</aff>
<author-notes>
<corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break></break>
Michel De Waard, Institut du Thorax, INSERM UMR1087, Nantes, France.<break></break>
Email: <email>michel.dewaard@univ-nantes.fr</email><break></break></corresp>
<fn fn-type="equal" id="brb3978-note-1002">
<label>†</label>
<p>These authors contributed equally to this work.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>22</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="collection">
<month>8</month>
<year>2018</year>
</pub-date>
<volume>8</volume>
<issue>8</issue>
<issue-id pub-id-type="doi">10.1002/brb3.2018.8.issue-8</issue-id>
<elocation-id>e00978</elocation-id>
<history>
<date date-type="received">
<day>19</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>01</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 Published by Wiley Periodicals, Inc. <copyright-statement>-->
<copyright-statement content-type="article-copyright">© 2018 The Authors. <italic>Brain and Behavior</italic> published by Wiley Periodicals, Inc.</copyright-statement>
<license license-type="creativeCommonsBy">
<license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p>
</license>
</permissions>
<self-uri content-type="pdf" xlink:href="file:BRB3-8-e00978.pdf" xlink:type="simple"></self-uri>
<abstract id="brb3978-abs-0001">
<title>Abstract</title>
<sec id="brb3978-sec-0001">
<title>Background</title>
<p>Autism spectrum disorder (<styled-content style="fixed-case">ASD</styled-content>) comprises a group of neurodevelopmental psychiatric disorders characterized by deficits in social interactions, interpersonal communication, repetitive and stereotyped behaviors and may be associated with intellectual disabilities. The description of <styled-content style="fixed-case">ASD</styled-content> as a synaptopathology highlights the importance of the synapse and the implication of ion channels in the etiology of these disorders.</p>
</sec>
<sec id="brb3978-sec-0002">
<title>Methods</title>
<p>A narrative and critical review of the relevant papers from 1982 to 2017 known by the authors was conducted.</p>
</sec>
<sec id="brb3978-sec-0003">
<title>Results</title>
<p>Genome‐wide linkages, association studies, and genetic analyses of patients with <styled-content style="fixed-case">ASD</styled-content> have led to the identification of several candidate genes and mutations linked to <styled-content style="fixed-case">ASD</styled-content>. Many of the candidate genes encode for proteins involved in neuronal development and regulation of synaptic function including ion channels and actors implicated in synapse formation. The involvement of ion channels in <styled-content style="fixed-case">ASD</styled-content> is of great interest as they represent attractive therapeutic targets. In agreement with this view, recent findings have shown that drugs modulating ion channel function are effective for the treatment of certain types of patients with <styled-content style="fixed-case">ASD</styled-content>.</p>
</sec>
<sec id="brb3978-sec-0004">
<title>Conclusion</title>
<p>This review describes the genetic aspects of <styled-content style="fixed-case">ASD</styled-content> with a focus on genes encoding ion channels and highlights the therapeutic implications of ion channels in the treatment of <styled-content style="fixed-case">ASD</styled-content>.</p>
</sec>
</abstract>
<kwd-group kwd-group-type="author-generated">
<kwd id="brb3978-kwd-0001">autism</kwd>
<kwd id="brb3978-kwd-0002">autism spectrum disorder</kwd>
<kwd id="brb3978-kwd-0003">genetics</kwd>
<kwd id="brb3978-kwd-0004">ion channels</kwd>
<kwd id="brb3978-kwd-0005">synapse formation</kwd>
<kwd id="brb3978-kwd-0006">synaptopathology</kwd>
<kwd id="brb3978-kwd-0007">therapeutic targets</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>Agence Nationale de la Recherche</funding-source>
<award-id>ANR‐11‐LABX‐0015</award-id>
</award-group>
</funding-group>
<counts>
<fig-count count="1"></fig-count>
<table-count count="3"></table-count>
<page-count count="18"></page-count>
<word-count count="14577"></word-count>
</counts>
<custom-meta-group>
<custom-meta>
<meta-name>source-schema-version-number</meta-name>
<meta-value>2.0</meta-value>
</custom-meta>
<custom-meta>
<meta-name>component-id</meta-name>
<meta-value>brb3978</meta-value>
</custom-meta>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>August 2018</meta-value>
</custom-meta>
<custom-meta>
<meta-name>details-of-publishers-convertor</meta-name>
<meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.4 mode:remove_FC converted:10.08.2018</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
<notes>
<p content-type="self-citation">
<mixed-citation id="brb3978-cit-1001" publication-type="journal">
<string-name>
<surname>Daghsni</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fajloun</surname>
<given-names>Z</given-names>
</string-name>, et al. <article-title>Autism throughout genetics: Perusal of the implication of ion channels</article-title>. <source xml:lang="en"/>Brain Behav. <year>2018</year>;<volume>8</volume>:<elocation-id>e00978</elocation-id>
<pub-id pub-id-type="doi">10.1002/brb3.978</pub-id>
</mixed-citation>
</p>
<fn-group id="brb3978-ntgp-0001">
<fn fn-type="funding" id="brb3978-note-1001">
<p>
<bold>Funding information</bold>
</p>
<p>M.D.W. is part of the laboratory of Excellence “Ion Channels, Science and Therapeutics” and is supported by a grant from the Agence Nationale de la Recherche (grant No. ANR‐11‐LABX‐0015)</p>
</fn>
</fn-group>
</notes>
</front>
<body>
<sec id="brb3978-sec-0005">
<label>1</label>
<title>BACKGROUND</title>
<p>For several decades, autism was described as an infantile psychiatric disorder and was termed “childhood schizophrenia.” It was initially believed to be triggered by the psychopathological behavior of the parents and in particular by the behavior of the mother toward her child (Sanua, <xref ref-type="ref" rid="brb3978-bib-0104">1983</xref>). In 1943, Leo Kanner characterized for the first time several cases of autism by describing the behavior of children between 2 and 8 years of age (Sanua, <xref ref-type="ref" rid="brb3978-bib-0104">1983</xref>). These children were characterized by deficits in social interactions and communication skills including eye contact avoidance, difficulties in understanding the emotions of others, hyper or hypo‐reactivity, focused interests, and stereotyped repetitive behaviors. Because the clinical manifestation of autism may differ significantly among patients, various pathologies were initially described including early infantile autism, childhood autism, Kanner's autism, high functioning autism, atypical autism, pervasive developmental disorder not otherwise specified, childhood disintegrative disorder, and Asperger disorder. This group of disorders is currently encompassed within autism spectrum disorder (ASD; American Psychiatric Association, <xref ref-type="ref" rid="brb3978-bib-0001">2013</xref>). The essential clinical manifestations of ASD are persistent in reciprocal social communication and social interaction and restrictive patterns of behavior, interests, or activities. These clinical features may be caused by a variety of genetic abnormalities and environmental factors and may also temporarily overlap with other disorders including Rett syndrome (Park et al., <xref ref-type="ref" rid="brb3978-bib-0089">2016</xref>). ASD may be also associated with epilepsy (15%–47% of cases) and intellectual disability (8%–39% of cases; Ko, Kim, Kim, Song, &amp; Cheon, <xref ref-type="ref" rid="brb3978-bib-0053">2016</xref>; La Malfa, Lassi, Bertelli, Salvini, &amp; Placidi, <xref ref-type="ref" rid="brb3978-bib-0058">2004</xref>).</p>
<p>Genetic causes of ASD were first identified by epidemiological studies of human populations diagnosed with autism (Szatmari, Jones, Zwaigenbaum, &amp; MacLean, <xref ref-type="ref" rid="brb3978-bib-0114">1998</xref>). Ozonoff et al. (<xref ref-type="ref" rid="brb3978-bib-0087">2011</xref>) demonstrated that the prevalence of autism among siblings was 18 times higher than in the general population, suggesting the existence of a familial heritability factor. Also, the imbalance in the sex ratio among ASD cases, with four to five boys affected for each affected girl, has led to the suggestion of a segregation linked to a sex chromosome and the implication of genes whose variations are expressed on a sex‐linked recessive mode (Lai, Lombardo, Auyeung, Chakrabarti, &amp; Baron‐Cohen, <xref ref-type="ref" rid="brb3978-bib-0059">2015</xref>; Ozonoff et al., <xref ref-type="ref" rid="brb3978-bib-0087">2011</xref>). The second argument in favor of genetic causes of ASD is based on the observation of a change in concordance rate between monozygotic and dizygotic twins, which was found to be 70%–90% in monozygotic twins compared with a lower rate of 0%–30% for dizygotic twins (Ronald &amp; Hoekstra, <xref ref-type="ref" rid="brb3978-bib-0097">2014</xref>; Rosenberg et al., <xref ref-type="ref" rid="brb3978-bib-0100">2009</xref>). Thirdly, the existence of chromosomal aberrations detected in patients with ASD also points toward genetic causes (Vorstman et al., <xref ref-type="ref" rid="brb3978-bib-0124">2006</xref>). Finally, genome‐wide association studies (GWAS) have led to the identification of numerous ASD susceptibility genes that are located on various chromosomes, especially 2q, 5p, 7q, 15q, 17q and on chromosome X (Anney et al., <xref ref-type="ref" rid="brb3978-bib-0002">2010</xref>).</p>
<p>In addition, some patients with ASD were found to have variations in syndromic Mendelian genes (e.g., <italic>FMR1</italic> for fragile X syndrome, <italic>TSC1</italic> and <italic>TSC2</italic> for tuberous sclerosis, and <italic>MECP2</italic> for Rett syndrome; Liu &amp; Takumi, <xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>). The identification of variations in neuroligin genes (<italic>NLGN4X</italic> and <italic>NLGN3X</italic>) in patients with ASD suggested that proteins involved in synapse formation and synaptic transmission play an important role in the etiology of ASD (Jamain et al., <xref ref-type="ref" rid="brb3978-bib-0047">2003</xref>). Similarly, rare variations have been detected in genes coding for ion channels (e.g., <italic>CACNA1</italic> and <italic>CACNB2</italic>), as well as proteins involved in synaptic structure, gene transcription, and chromatin remodeling (e.g., <italic>NRXN1</italic>,<italic> CTTNBP2, CHD8,</italic> and <italic>SHANK3</italic>), indicating that altered synaptic plasticity and regulation of gene expression may also be involved in the etiology of ASD (Cross‐Disorder Group of the Psychiatric Genomics Consortium, <xref ref-type="ref" rid="brb3978-bib-0022">2013</xref>; De Rubeis et al., <xref ref-type="ref" rid="brb3978-bib-0023">2014</xref>; Durand et al., <xref ref-type="ref" rid="brb3978-bib-0032">2007</xref>).</p>
<p>This review examines the genetic basis of ASD and highlights the involvement of ion channel dysfunctions in the causes of this disorder.</p>
</sec>
<sec id="brb3978-sec-0006">
<label>2</label>
<title>REVIEW</title>
<sec id="brb3978-sec-0007">
<label>2.1</label>
<title>Genetic aspects of ASD</title>
<p>During the last 30 years, a number of reviews have provided detailed description of the genetic architecture associated with ASD (Bourgeron, <xref ref-type="ref" rid="brb3978-bib-0012">2015</xref>; Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>; Li, Zou, &amp; Brown, <xref ref-type="ref" rid="brb3978-bib-0068">2012</xref>; Liu &amp; Takumi, <xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>; Persico &amp; Napolioni, <xref ref-type="ref" rid="brb3978-bib-0090">2013</xref>; Robert et al., <xref ref-type="ref" rid="brb3978-bib-0095">2017</xref>). This expansion of knowledge is due to the advances in molecular technologies, which allowed detecting chromosomal rearrangements, copy number variations (CNVs), and candidate genes in patients with ASD.</p>
<sec id="brb3978-sec-0008">
<label>2.1.1</label>
<title>Chromosomal abnormalities and CNVs in ASD</title>
<p>Chromosomal rearrangements have been identified in 5% of individuals with ASD. These cytogenetic abnormalities are observed in chromosomes 5p15, 15q11–q13, 17p11, and 22q11.2 (Jacquemont et al., <xref ref-type="ref" rid="brb3978-bib-0046">2006</xref>; Sebat et al., <xref ref-type="ref" rid="brb3978-bib-0106">2007</xref>). Abnormalities affecting the 15q11–q13 region represent the most frequent variation associated with ASD accounting for close to 1% of all ASD cases (Badescu et al., <xref ref-type="ref" rid="brb3978-bib-0004">2016</xref>). Depending on the variation type and pattern of inheritance, this locus is associated with either Prader–Willi syndrome (PWS) or Angelman syndrome (AS) along with ASD (Badescu et al., <xref ref-type="ref" rid="brb3978-bib-0004">2016</xref>). This variation is based on whether the duplication affects the maternal or the paternal allele (Badescu et al., <xref ref-type="ref" rid="brb3978-bib-0004">2016</xref>). Besides structural rearrangements, other abnormalities of chromosomal numbers or aneuploidies are detected in ASD including trisomy 21, Turner syndrome (45, X), and Klinefelter syndrome (47, XXY; Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>). Thanks to the comparative genomic hybridization (CGH) technique or SNPs array, CNVs were also found in multiple chromosomal regions at 1q21.1, 16p11.2, 17q12, and 22q11.2 (Jacquemont et al., <xref ref-type="ref" rid="brb3978-bib-0046">2006</xref>; Marshall et al., <xref ref-type="ref" rid="brb3978-bib-0074">2008</xref>; Matsunami et al., <xref ref-type="ref" rid="brb3978-bib-0076">2013</xref>; O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0086">2012</xref>; Pinto et al., <xref ref-type="ref" rid="brb3978-bib-0093">2010</xref>; Sebat et al., <xref ref-type="ref" rid="brb3978-bib-0106">2007</xref>). Further studies supported the association with ASD of two recurrent de novo CNVs at 16p11.2 (duplication and deletion) and 7q11.23 (duplication; Levy et al., <xref ref-type="ref" rid="brb3978-bib-0064">2011</xref>; Sanders Stephan et al., <xref ref-type="ref" rid="brb3978-bib-0102">2011</xref>). The chromosomal deletion found at 7q11.23 has been linked to William's syndrome, which includes intellectual disabilities, facial dysmorphic features, congenital heart defect, and transient hypercalcemia. The intellectual disabilities suggest that this chromosomal region may also contain genes associated with social behaviors (Pinto et al., <xref ref-type="ref" rid="brb3978-bib-0093">2010</xref>). CNVs were found enriched in groups of genes implicated in cell signaling pathways that regulate neuronal development and cell proliferation along with a group of genes associated with the GTPase/Ras signaling pathway and neuronal plasticity (Pinto et al., <xref ref-type="ref" rid="brb3978-bib-0093">2010</xref>). CNVs studies demonstrated also that there is alteration in the fragile X mental retardation protein (FMRP) in patients with ASD. In fact, fragile X syndrome (X‐Fra) is associated with 1%–2% of ASD cases. X‐Fra syndrome is the second major cause of intellectual disability, which is caused by the expansion of CGG trinucleotide repeats in the <italic>FMR1</italic> gene located on chromosome X and that encodes FMRP. This protein plays an essential role in synaptic plasticity by regulating mRNA trafficking in the brain (Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>; Roberts, Tonnsen, McCary, Caravella, &amp; Shinkareva, <xref ref-type="ref" rid="brb3978-bib-0096">2016</xref>).</p>
<p>These data emphasized the role of CNVs in ASD, and further investigations in these regions have led to the identification of candidate genes in particular with whole‐exome and whole‐genome sequencing studies.</p>
</sec>
<sec id="brb3978-sec-0009">
<label>2.1.2</label>
<title>ASD candidate genes</title>
<p>Next‐generation sequencing (NGS) techniques are very efficient tools for the identification of novel candidate genes associated with ASD. Most of the studies have been performed on sporadic cases of ASD. Using NGS, O'Rack et al. identified de novo variations in <italic>FOXP1</italic>,<italic> GRIN2B</italic>,<italic> SCN1A</italic>,<italic> LAMC3,</italic> and rare inherited <italic>CNTNAP2</italic> variations (De Rubeis et al., <xref ref-type="ref" rid="brb3978-bib-0023">2014</xref>; O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0084">2011</xref>). Three genes were found in ASD probands with two de novo variations in each of these genes: <italic>BRCA2</italic>,<italic> FAT1,</italic> and <italic>KCNMA1</italic> (Neale et al., <xref ref-type="ref" rid="brb3978-bib-0083">2012</xref>). These studies also found significant enrichment of de novo variations in five ASD candidate genes including <italic>STXBP1</italic>,<italic> MEF2C</italic>,<italic> KIRREL3</italic>,<italic> RELN,</italic> and <italic>TUBA1A</italic> (Neale et al., <xref ref-type="ref" rid="brb3978-bib-0083">2012</xref>). Likewise, a region of chromosome 7q that includes the candidate genes <italic>RELN</italic>,<italic> FOXP2</italic>,<italic> WNT2,</italic> and <italic>CADPS2</italic> has been implicated in ASD (Liu &amp; Takumi, <xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>). The extracellular glycoprotein RELN plays a key role in neuronal migration and cell interactions (Li et al., <xref ref-type="ref" rid="brb3978-bib-0065">2004</xref>). However, it appears that variations in <italic>RELN</italic> are insufficient to cause ASD, suggesting that secondary genetic or epigenetic factors are behind these cases of ASD (Li et al., <xref ref-type="ref" rid="brb3978-bib-0065">2004</xref>). <italic>FOXP2</italic> is a crucial gene for language development. Variations affecting this gene have been detected in individuals who lack the ability of acquiring communication skills. However, evidence supporting the involvement of <italic>FOXP2</italic> in ASD remains scattered (Toma et al., <xref ref-type="ref" rid="brb3978-bib-0116">2013</xref>). The <italic>WNT2</italic> gene belongs to the large <italic>WNT</italic> gene family, which is highly expressed during development of the central nervous system and, therefore, it is not surprising that it could represent an ASD candidate gene (Kalkman, <xref ref-type="ref" rid="brb3978-bib-0049">2012</xref>; Li et al., <xref ref-type="ref" rid="brb3978-bib-0065">2004</xref>). Finally, the <italic>CADPS2</italic> gene encodes a calcium (Ca<sup>2+</sup>)‐binding protein and variations in this gene have been linked to patients with ASD and intellectual disability (Bonora et al., <xref ref-type="ref" rid="brb3978-bib-0011">2014</xref>). Others genes encoding synaptic proteins linked to ASD were also identified by NGS: They include the glutamate receptors (GRIK2, GRIA3), the cell adhesion molecule CNTNAP2, and the scaffolding protein SHANK3. SHANK3 is involved in (i) synapse formation and maturation, (ii) the link between neurotransmitter receptors and ion channels, and (iii) the interaction with scaffolding proteins and gene regulatory proteins (e.g., protein of chromatin remodeling CHD8; Anney et al., <xref ref-type="ref" rid="brb3978-bib-0002">2010</xref>; Cotney et al., <xref ref-type="ref" rid="brb3978-bib-0020">2015</xref>; De Rubeis et al., <xref ref-type="ref" rid="brb3978-bib-0023">2014</xref>; O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0084">2011</xref>). <italic>NRXN1</italic>,<italic> NLGN3/4X,</italic> and <italic>SHANK3</italic> genes, which encode proteins involved in neuronal cell adhesion and in the regulation of synaptic transmission, are considered strong candidate loci for ASD (Weiss &amp; Arking, <xref ref-type="ref" rid="brb3978-bib-0126">2009</xref>). Variations in those loci have also been detected in several patients with ASD (Anney et al., <xref ref-type="ref" rid="brb3978-bib-0002">2010</xref>; O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0084">2011</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0001">1</xref>).</p>
<table-wrap id="brb3978-tbl-0001" orientation="portrait" position="float" xml:lang="en">
<label>Table 1</label>
<caption>
<p>Major genes implicated in autism spectrum disorder (ASD)</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">Name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Cytogenetic location</th>
<th align="left" colspan="1" rowspan="1" valign="top">Protein function</th>
<th align="left" colspan="1" rowspan="1" valign="top">Associated pathologies</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CHD8</italic>
</td>
<td align="left" colspan="1" rowspan="1">Chromodomain helicase DNA‐binding protein 8/autism susceptibility 18 (AUT18)</td>
<td align="left" colspan="1" rowspan="1">14q11.2</td>
<td align="left" colspan="1" rowspan="1">Transcriptional repressor negatively regulates Wnt signaling pathway by binding to beta‐catenin thereby inhibiting binding to TCF4</td>
<td align="left" colspan="1" rowspan="1">ASD</td>
<td align="left" colspan="1" rowspan="1">Cotney et al. (<xref ref-type="ref" rid="brb3978-bib-0020">2015</xref>), Krumm, O'Roak, Shendure, and Eichler (<xref ref-type="ref" rid="brb3978-bib-0055">2014</xref>), and O'Roak et al. (<xref ref-type="ref" rid="brb3978-bib-0085">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CNTNAP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Contactin‐associated protein‐like 2/autism susceptibility 15 (AUT15)</td>
<td align="left" colspan="1" rowspan="1">7q35–q36</td>
<td align="left" colspan="1" rowspan="1">Protein member of the neurexin superfamily involved in neural and glia interactions and clustering of potassium channels in neurons</td>
<td align="left" colspan="1" rowspan="1">Epilepsy, Pitt–Hopkins‐like syndrome 1, ASD</td>
<td align="left" colspan="1" rowspan="1">O'Roak et al. (<xref ref-type="ref" rid="brb3978-bib-0084">2011</xref>) and Toma et al. (<xref ref-type="ref" rid="brb3978-bib-0116">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CTTNBP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Cortactin‐binding protein 2</td>
<td align="left" colspan="1" rowspan="1">7q31.31</td>
<td align="left" colspan="1" rowspan="1">Modulates the mobility of cortactin in neurons. Regulates spine morphogenesis and synaptic signaling via PP2A complex</td>
<td align="left" colspan="1" rowspan="1">ASD</td>
<td align="left" colspan="1" rowspan="1">Cross‐Disorder Group of the Psychiatric Genomics Consortium (<xref ref-type="ref" rid="brb3978-bib-0022">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>FMR1</italic>
</td>
<td align="left" colspan="1" rowspan="1">Fragile X mental retardation protein</td>
<td align="left" colspan="1" rowspan="1">Xq27.3</td>
<td align="left" colspan="1" rowspan="1">FMRP is an RNA‐binding protein involved in RNA translation in neurons</td>
<td align="left" colspan="1" rowspan="1">Fragile X syndrome, ASD</td>
<td align="left" colspan="1" rowspan="1">Devlin and Scherer (<xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>) and Roberts et al. (<xref ref-type="ref" rid="brb3978-bib-0096">2016</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>MECP2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Methyl‐CpG‐binding protein 2</td>
<td align="left" colspan="1" rowspan="1">Xq28</td>
<td align="left" colspan="1" rowspan="1">Chromatin‐associated protein that regulates gene transcription. It is required for the maturation of neurons</td>
<td align="left" colspan="1" rowspan="1">Rett syndrome, mental retardation X‐linked syndromic 13, autism susceptibility X‐linked 3</td>
<td align="left" colspan="1" rowspan="1">Devlin and Scherer (<xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>) and Liu and Takumi (<xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>NLGN3</italic>
</td>
<td align="left" colspan="1" rowspan="1">Neuroligin 3</td>
<td align="left" colspan="1" rowspan="1">Xq13.1</td>
<td align="left" colspan="1" rowspan="1">Linked only to glutamatergic postsynaptic proteins</td>
<td align="left" colspan="1" rowspan="1">Asperger syndrome susceptibility, autism susceptibility X‐linked 1</td>
<td align="left" colspan="1" rowspan="1">Jamain et al. (<xref ref-type="ref" rid="brb3978-bib-0047">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>NLGN4</italic>
</td>
<td align="left" colspan="1" rowspan="1">Neuroligin 4</td>
<td align="left" colspan="1" rowspan="1">Xp22.32–p22.31</td>
<td align="left" colspan="1" rowspan="1">Binds to neurexins and localized in dendritic spines</td>
<td align="left" colspan="1" rowspan="1">Mental retardation X‐linked, Asperger syndrome susceptibility X‐linked, autism susceptibility X‐linked 2</td>
<td align="left" colspan="1" rowspan="1">Jamain et al. (<xref ref-type="ref" rid="brb3978-bib-0047">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>NRXN1</italic>
</td>
<td align="left" colspan="1" rowspan="1">Neurexin 1</td>
<td align="left" colspan="1" rowspan="1">2p16.3</td>
<td align="left" colspan="1" rowspan="1">Neurexins, including NRXN1, are cell surface receptors that bind neuroligins to form a Ca<sup>2+</sup>‐dependent neurexin/neuroligin complex at synapses in the central nervous system. This complex is required for neurotransmission and is involved in the formation of synaptic connexion</td>
<td align="left" colspan="1" rowspan="1">Pitt–Hopkins‐like syndrome 2, schizophrenia, ASD</td>
<td align="left" colspan="1" rowspan="1">Anney et al. (<xref ref-type="ref" rid="brb3978-bib-0002">2010</xref>) and Girirajan et al. (<xref ref-type="ref" rid="brb3978-bib-0037">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>PTEN</italic>
</td>
<td align="left" colspan="1" rowspan="1">Phosphatase and tension homolog</td>
<td align="left" colspan="1" rowspan="1">10q23.31</td>
<td align="left" colspan="1" rowspan="1">Tumor suppressor involved in PI3K signaling pathway and negatively regulates the MAPK pathway</td>
<td align="left" colspan="1" rowspan="1">PTEN hamartoma tumor syndrome, macrocephaly, autism</td>
<td align="left" colspan="1" rowspan="1">McBride et al. (<xref ref-type="ref" rid="brb3978-bib-0077">2010</xref>) and O'Roak et al. (<xref ref-type="ref" rid="brb3978-bib-0085">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SHANK3</italic>
</td>
<td align="left" colspan="1" rowspan="1">SH3 and multiple ankyrin repeat domains 3</td>
<td align="left" colspan="1" rowspan="1">22q13.33</td>
<td align="left" colspan="1" rowspan="1">Scaffold protein abundant in postsynaptic excitatory synapses where it organizes receptor signaling (e.g., NMDA receptor, mGluR)</td>
<td align="left" colspan="1" rowspan="1">ASD, Phelan–McDermid syndrome, schizophrenia</td>
<td align="left" colspan="1" rowspan="1">Durand et al. (<xref ref-type="ref" rid="brb3978-bib-0032">2007</xref>) and Yi et al. (<xref ref-type="ref" rid="brb3978-bib-0130">2016</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SYNGAP1</italic>
</td>
<td align="left" colspan="1" rowspan="1">Synaptic Ras GTPase‐activating protein 1</td>
<td align="left" colspan="1" rowspan="1">6p21.32</td>
<td align="left" colspan="1" rowspan="1">Ras GTPase‐activating protein that is largely localized in dendritic spines in neocortical pyramidal neurons. Suppresses signaling pathways linked to NMDA receptor (NMDAR)‐mediated synaptic plasticity and AMPA receptor (AMPAR)</td>
<td align="left" colspan="1" rowspan="1">Mental retardation, ASD</td>
<td align="left" colspan="1" rowspan="1">Pinto et al. (<xref ref-type="ref" rid="brb3978-bib-0093">2010</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>TSC1</italic>
</td>
<td align="left" colspan="1" rowspan="1">Hamartin</td>
<td align="left" colspan="1" rowspan="1">9q34.13</td>
<td align="left" colspan="1" rowspan="1">Interacts with tuberin to form a complex that inhibits signal transduction to the downstream effectors of the mammalian target rapamycin pathway (mTOR). Implicated in cell proliferation inhibition</td>
<td align="left" colspan="1" rowspan="1">Tuberous sclerosis‐1</td>
<td align="left" colspan="1" rowspan="1">Devlin and Scherer (<xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>) and Liu and Takumi (<xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>TSC2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Tuberin</td>
<td align="left" colspan="1" rowspan="1">16p13.3</td>
<td align="left" colspan="1" rowspan="1">Acts as a chaperone for hamartin protein</td>
<td align="left" colspan="1" rowspan="1">Tuberous sclerosis‐2</td>
<td align="left" colspan="1" rowspan="1">Devlin and Scherer (<xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>) and Liu and Takumi (<xref ref-type="ref" rid="brb3978-bib-0069">2014</xref>)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>These approaches have also identified variants in genes encoding ion channels. Here, we describe these variations and highlight the role of ion channels in ASD.</p>
</sec>
</sec>
<sec id="brb3978-sec-0010">
<label>2.2</label>
<title>Ion channels and ASD</title>
<sec id="brb3978-sec-0011">
<label>2.2.1</label>
<title>Calcium signaling and voltage‐gated Ca<sup>2+</sup> channels in ASD</title>
<p>Ca<sup>2+</sup> channels are present in many different cell types and they mediate Ca<sup>2+</sup> influx in response to stimuli which can be a response to (i) change in the membrane depolarization; known as voltage‐gated channels or (ii) to a ligand‐mediated activation (e.g., ryanodine receptor (RyR), inositol triphosphate receptor (IP3R) in the reticulum). In the brain, the elevation of intracellular Ca<sup>2+</sup> concentration activates several signaling pathways that regulate important neuronal functions such as synaptogenesis, neuronal differentiation, and cell migration (Krey &amp; Dolmetsch, <xref ref-type="ref" rid="brb3978-bib-0054">2007</xref>). Dysfunctions of these pathways are responsible for abnormalities observed in patients with ASD, which include an increased cell density, changes in neuronal size, dendritic and axonal branching alterations, as well as in neuronal connectivity (Krey &amp; Dolmetsch, <xref ref-type="ref" rid="brb3978-bib-0054">2007</xref>). Voltage‐gated Ca<sup>2+</sup> channels are devised in two categories: high‐voltage‐activated channels (HVA) and low‐voltage‐activated channels (LVA). HVA include L‐type, the neuronal N‐, P/Q‐, and R‐type. The low‐voltage‐activated Ca<sup>2+</sup> currents are represented by T‐type channels. HVA are composed by a principal transmembrane subunit α1 (Cav α) associated with a disulfide‐linked α2δ (Cav α2δ) dimer, an intracellular β subunit (Cav β), and a transmembrane γ subunit (Cav γ), while LVA channels are composed only by α1 subunit. Both of HVA and LVA channels control the passive flow of Ca<sup>2+</sup> across membranes. Therefore, alteration in their components leads to defective channel function that translates themselves into a variety of neurological disorders including hemiplegic migraine, episodic and spinocerebellar ataxia, epilepsy, and ASD (Bidaud, Mezghrani, Swayne, Monteil, &amp; Lory, <xref ref-type="ref" rid="brb3978-bib-0009">2006</xref>; Breitenkamp, Matthes, &amp; Herzig, <xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>; Heyes et al., <xref ref-type="ref" rid="brb3978-bib-0042">2015</xref>; Parellada et al., <xref ref-type="ref" rid="brb3978-bib-0088">2014</xref>; Stary et al., <xref ref-type="ref" rid="brb3978-bib-0113">2008</xref>; Zamponi, <xref ref-type="ref" rid="brb3978-bib-0131">2016</xref>).</p>
<p>The Timothy syndrome (TS) is a channelopathy described to be associated with ASD. TS is a multisystem disorder characterized by autistic features, cardiac abnormalities (QT prolongation), defective immune response, and syndactyly (Splawski et al., <xref ref-type="ref" rid="brb3978-bib-0110">2004</xref>). Variations affecting the gene encoding the pore‐forming α<sub>1</sub> subunit of L‐type voltage‐gated Ca<sup>2+</sup> channels are associated with TS. Two genetic variations (G406R and G402S), affecting exon 8 of the Ca<sub>v</sub>1.2 channel α<sub>1</sub> subunit gene (<italic>CACNA1C</italic>), have been associated with TS. They impair the Ca<sub>v</sub>1.2 inactivation and lead to prolonged channel opening and consequent increase in Ca<sup>2+</sup> flux (Barrett &amp; Tsien, <xref ref-type="ref" rid="brb3978-bib-0006">2008</xref>; Splawski et al., <xref ref-type="ref" rid="brb3978-bib-0110">2004</xref>). Whole‐exome sequencing of a male patient affected with TS revealed a novel variation in <italic>CACNA1C</italic> gene (p.I1166T; Boczek et al., <xref ref-type="ref" rid="brb3978-bib-0010">2015</xref>). Electrophysiological analysis of HEK‐293 cells expressing this gene variant showed a shift in the peak channel activation and a reduced current density (Boczek et al., <xref ref-type="ref" rid="brb3978-bib-0010">2015</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). L‐type channels are predominantly expressed in the heart and brain. They are localized at dendrites and cell bodies of mature neurons and regulate neuronal excitability and Ca<sup>2+</sup>‐dependent signaling cascades involving cAMP‐binding protein (CREB) and myocyte enhancer factor 2 (MEF2; Krey &amp; Dolmetsch, <xref ref-type="ref" rid="brb3978-bib-0054">2007</xref>; Simms &amp; Zamponi, <xref ref-type="ref" rid="brb3978-bib-0107">2014</xref>). <italic>CACNA1C</italic> plays a key role in the development and functionality of the central nervous system by modulating gamma‐aminobutyric acid (GABA) transmission and influencing neuronal firing. In fact, mice with dysfunctional <italic>CACNA1C</italic> show defects in <italic>N</italic>‐methyl‐<sc>d</sc>‐aspartate (NMDA) receptor activity leading to an NMDA‐independent long‐term potentiation in the CA1 region of the hippocampus that produces an acute decline in memory. These observations indicate that <italic>CACNA1C</italic> may play a role in NMDA receptor‐dependent signaling and in synaptic plasticity in the hippocampus. In addition to ASD, SNPs in <italic>CACNA1C</italic> gene are linked to psychiatric disorders including schizophrenia and bipolar disorder (Li et al., <xref ref-type="ref" rid="brb3978-bib-0067">2015</xref>; Moosmang et al., <xref ref-type="ref" rid="brb3978-bib-0080">2005</xref>). In a large GWAS, two genes encoding the α<sub>1</sub> subunit of calcium channel (<italic>CACNA1C)</italic> and its regulatory β<sub>2</sub> subunit (<italic>CACNB2)</italic> were strongly linked to psychiatric disorders and ASD (Cross‐Disorder Group of the Psychiatric Genomics Consortium, <xref ref-type="ref" rid="brb3978-bib-0022">2013</xref>).</p>
<table-wrap id="brb3978-tbl-0002" orientation="portrait" position="float" xml:lang="en">
<label>Table 2</label>
<caption>
<p>Impact of genetic variations associated with autism spectrum disorder (ASD) on ion channel's function</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Ion channels</th>
<th align="left" colspan="1" rowspan="1" valign="top">Genes</th>
<th align="left" colspan="1" rowspan="1" valign="top">Variations</th>
<th align="left" colspan="1" rowspan="1" valign="top">Type of variation</th>
<th align="left" colspan="1" rowspan="1" valign="top">Impact on ion channel</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="5">Ca<sup>2+</sup> channels</td>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1C</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.I1166T</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">Shifts peak channel activation and reduces current density</td>
<td align="left" colspan="1" rowspan="1">Boczek et al. (<xref ref-type="ref" rid="brb3978-bib-0010">2015</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1D</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.A749G; p.G407R</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">Changes kinetics of activation and inactivation</td>
<td align="left" colspan="1" rowspan="1">Pinggera et al. (<xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1F</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.I745T</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">Shifts channel inactivation ~30 mV and significantly slows the inactivation kinetics</td>
<td align="left" colspan="1" rowspan="1">Hemara‐Wahanui et al. (<xref ref-type="ref" rid="brb3978-bib-0041">2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1H</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.R212C; p.R902W, p.R1871Q/p.A1874V; p.W962C</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">All these mutations reduce current density and voltage‐dependent gating properties</td>
<td align="left" colspan="1" rowspan="1">Splawski et al. (<xref ref-type="ref" rid="brb3978-bib-0111">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNB2</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.G167S; p.S197F;p.F240L</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">G167S and S197F increase the sensitivity of voltage‐dependent inactivation, and F240L shows an accelerated time‐dependent inactivation</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0014">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="3">K<sup>+</sup> channels</td>
<td align="left" colspan="1" rowspan="1">
<italic>KCNMA1</italic>
</td>
<td align="left" colspan="1" rowspan="1">9q23/10q22</td>
<td align="left" colspan="1" rowspan="1">Translocation</td>
<td align="left" colspan="1" rowspan="1">Reduces the activity of the BK<sub>Ca</sub> channel</td>
<td align="left" colspan="1" rowspan="1">Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNB1</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.I199F</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">Induces partial loss of function relative to biophysical defects of assembled homotetrameric and heterotetrameric channels</td>
<td align="left" colspan="1" rowspan="1">Calhoun et al. (<xref ref-type="ref" rid="brb3978-bib-0016">2017</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNQ3</italic>
</td>
<td align="left" colspan="1" rowspan="1">p.P574S</td>
<td align="left" colspan="1" rowspan="1">Missense</td>
<td align="left" colspan="1" rowspan="1">Reduces potassium current amplitude</td>
<td align="left" colspan="1" rowspan="1">Gilling et al. (<xref ref-type="ref" rid="brb3978-bib-0036">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Na<sup>+</sup> channels</td>
<td align="left" colspan="1" rowspan="1">
<italic>SCN2A</italic>
</td>
<td align="left" colspan="1" rowspan="1">c.476+1G&gt;A</td>
<td align="left" colspan="1" rowspan="1">Splicing</td>
<td align="left" colspan="1" rowspan="1">Produces a nonsense mRNA and a truncated protein which alters the channel properties</td>
<td align="left" colspan="1" rowspan="1">Tavassoli et al. (<xref ref-type="ref" rid="brb3978-bib-0115">2014</xref>)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>In addition, three rare missense variations of <italic>CACNB2</italic> (G167S, S197F, and F240L) were identified in families with ASD (Breitenkamp et al., <xref ref-type="ref" rid="brb3978-bib-0014">2014</xref>). Heterologous expression of these gene variants in HEK‐293 cells followed by electrophysiological analysis showed remarkable changes in channel kinetics characterized by an increased sensitivity of voltage‐dependent inactivation for both G167S and S197F variants. Unlike these variations, the third variation F240L showed a significant accelerated time‐dependent inactivation (Breitenkamp et al., <xref ref-type="ref" rid="brb3978-bib-0014">2014</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). A deletion in chromosome region 12p13.33, that affects both the <italic>CACNA1C</italic> and the <italic>CACNA2D4</italic> genes coding for the α<sub>1</sub> channel‐forming subunit and the α<sub>2</sub>δ<sub>4</sub> auxiliary subunit, respectively, was observed in patients with autistic manifestations (Smith et al., <xref ref-type="ref" rid="brb3978-bib-0109">2012</xref>). A chromosomal translocation of 2p:12p resulting in a deletion of both genes (<italic>CACNA1C</italic> and <italic>CACNA2D4</italic>) was detected in two ASD‐affected individuals (Smith et al., <xref ref-type="ref" rid="brb3978-bib-0109">2012</xref>). Furthermore, a whole‐exome sequencing study identified de novo rare alleles in α<sub>1</sub> subunit loci <italic>CACNA1D</italic> and <italic>CACNA1E</italic> (O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0086">2012</xref>; Pinggera et al., <xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>). The α<sub>1</sub> subunit (Ca<sub>v</sub>1.3) of L‐type channels plays an important role in neuronal signaling and in brain function including memory and behavior (Pinggera et al., <xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>). De novo variations in Ca<sub>v</sub>1.3 subunit (<italic>CACNA1D</italic>) were identified in a cohort of patients affected with autism along with intellectual disability (Pinggera et al., <xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>). Using heterologous expression of the mutant proteins in tsA‐201 cells and whole‐cell patch‐clamp electrophysiological recordings revealed that these genetic variations affect the gating properties of the channel by changing the voltage‐dependent kinetics of activation and inactivation (Pinggera et al., <xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). A relevant study based on the analysis of signaling pathways implicated in ASD etiology of 1000 individuals with ASD from the Autism Genetic Resource Exchange (AGRE) identified SNPs in 146 genes. From 15 high‐risk SNPs linked to ASD found in the study, two of them are found in <italic>CACNA1A</italic> encoding Ca<sub>V</sub>2.1 of Ca<sup>2+</sup> channel and in <italic>CACNA2D3</italic> gene encoding for α<sub>2</sub>δ<sub>3</sub> subunit of voltage‐gated Ca<sup>2+</sup> channel (Skafidas et al., <xref ref-type="ref" rid="brb3978-bib-0108">2014</xref>). A recent study in Chinese Han population reported for the first time the association of two markers (rs7249246 and rs12609735) in <italic>CACNA1A</italic> gene with patients with ASD (Li et al., <xref ref-type="ref" rid="brb3978-bib-0066">2015</xref>). A variation in <italic>CACNA1F</italic> gene encoding for Ca<sub>V</sub>1.4 of Ca<sup>2+</sup> channel was detected in a family with inherited night blindness and ASD. This variation leads to the substitution of threonine by an isoleucine residue at codon 745 (p.I745T). Functional analysis of this variation performed in tsA‐201 cells demonstrated that it affects channel kinetics causing the inactivation of the Ca<sup>2+</sup> current (Hemara‐Wahanui et al., <xref ref-type="ref" rid="brb3978-bib-0041">2005</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>).</p>
<p>T‐type voltage‐gated Ca<sup>2+</sup> channels are known to play a key role in the cerebral cortex and in the thalamus (Simms &amp; Zamponi, <xref ref-type="ref" rid="brb3978-bib-0107">2014</xref>). Four heterozygous missense variations in <italic>CACNA1H</italic> gene, encoding the Ca<sub>v</sub>3.2 subunit of T‐type channels, were found associated with decreased channel activity in six of 461 autistic patients. This decrease could be a result of abnormal trafficking of the channel (Splawski et al., <xref ref-type="ref" rid="brb3978-bib-0111">2006</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). Variations in the <italic>CACNA1H</italic> gene have also been associated with childhood absence epilepsy (Splawski et al., <xref ref-type="ref" rid="brb3978-bib-0111">2006</xref>). Another α<sub>1</sub> subunit of the T‐type calcium channel‐encoding gene (<italic>CACNA1G</italic>) mapped at 17q11–q21 region was found to contain SNPs (rs12603122, rs757415, rs12603112, and rs198547) in patients with ASD (Lu, Dai, Martinez‐Agosto, &amp; Cantor, <xref ref-type="ref" rid="brb3978-bib-0071">2012</xref>). A statistical re‐analysis of a GWAS data of patients with ASD from the AGRE revealed the association of the <italic>CACNA1I</italic> gene encoding for Ca<sub>V</sub>3.3 of Ca<sup>2+</sup> channel in ASD (Hussman et al., <xref ref-type="ref" rid="brb3978-bib-0045">2011</xref>). Yatsenko et al. studied 20 unrelated children affected with neurodevelopmental impairments, speech delay, and ASD using array‐comparative genome hybridization and detected a duplication in 9q34. This region contains the <italic>CACNA1B</italic> gene, and the 3′ region of <italic>EHMT1</italic> gene implicated in Kleefstra syndrome, which is a genetic disorder characterized by intellectual disabilities, infantile hypotonia, severe delay in expressive language, and facial dysmorphism associated with other clinical signs. However, this duplication was described by the author as “benign” because it was also found in the control individual (Yatsenko et al., <xref ref-type="ref" rid="brb3978-bib-0129">2012</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0003">3</xref>).</p>
<table-wrap id="brb3978-tbl-0003" orientation="portrait" position="float" xml:lang="en">
<label>Table 3</label>
<caption>
<p>Ion channel genes implicated in autism spectrum disorder (ASD) and related pathologies</p>
</caption>
<table frame="hsides" rules="groups">
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<col span="1" style="border-right:solid 1px #000000"/>
<thead valign="top">
<tr style="border-bottom:solid 1px #000000">
<th align="left" colspan="1" rowspan="1" valign="top">Genes</th>
<th align="left" colspan="1" rowspan="1" valign="top">Name</th>
<th align="left" colspan="1" rowspan="1" valign="top">Cytogenetic location</th>
<th align="left" colspan="1" rowspan="1" valign="top">Description</th>
<th align="left" colspan="1" rowspan="1" valign="top">Associated phenotypes</th>
<th align="left" colspan="1" rowspan="1" valign="top">References</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1A subunit of P/Q‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">19p13.13</td>
<td align="left" colspan="1" rowspan="1">Modulates the biophysical properties of P/Q‐type Ca<sup>2+</sup> channel in neurons</td>
<td align="left" colspan="1" rowspan="1">Autism, Asperger or PDD‐NOS, Ataxia, Migraine</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>) and Skafidas et al. (<xref ref-type="ref" rid="brb3978-bib-0108">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1B</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1B subunit of N‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">9q34.3</td>
<td align="left" colspan="1" rowspan="1">Modulates the biophysical properties of N‐type Ca<sup>2+</sup> channelwhich controls neurotransmitter release from neurons</td>
<td align="left" colspan="1" rowspan="1">Neurodevelopmental impairments, ASD, speech delay</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>) and Yatsenko et al. (<xref ref-type="ref" rid="brb3978-bib-0129">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1C</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1C subunit of L‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">12p13.33</td>
<td align="left" colspan="1" rowspan="1">Plays an important role in the development of the central nervous system and it functions, especially NMDA receptor function in the hippocampus. The mutation is also implicated in defective synaptic plasticity</td>
<td align="left" colspan="1" rowspan="1">Timothy syndrome, psychiatric diseases (bipolar disorder, schizophrenia), Brugada syndrome, ASD</td>
<td align="left" colspan="1" rowspan="1">Cross‐Disorder Group of the Psychiatric Genomics Consortium (<xref ref-type="ref" rid="brb3978-bib-0022">2013</xref>) and Li et al. (<xref ref-type="ref" rid="brb3978-bib-0067">2015</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1D</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1D subunit of voltage‐gated Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">3p21.1</td>
<td align="left" colspan="1" rowspan="1">Contributes to different brain functions, such as emotions, memory, and drug dependence. Controls gating and current properties and is involved in pacemaker current</td>
<td align="left" colspan="1" rowspan="1">Sinoatrial node dysfunction and deafness, psychiatric diseases, ASD</td>
<td align="left" colspan="1" rowspan="1">Pinggera et al. (<xref ref-type="ref" rid="brb3978-bib-0091">2015</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1E</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1E subunit of R‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">1q25.3</td>
<td align="left" colspan="1" rowspan="1">Modulates the biophysical properties of R‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">ASD, psychiatric diseases</td>
<td align="left" colspan="1" rowspan="1">Lu et al. (<xref ref-type="ref" rid="brb3978-bib-0071">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1F</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1F subunit of L‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">Xp11.23</td>
<td align="left" colspan="1" rowspan="1">Modulates the biophysical properties of L‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">Congenital night blindness and autism</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>) and Hemara‐Wahanui et al. (<xref ref-type="ref" rid="brb3978-bib-0041">2005</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1G</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1G subunit of T‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">17q21.33</td>
<td align="left" colspan="1" rowspan="1">Modulates the Ca<sup>2+</sup> influx of T‐type channel in neurons and muscle</td>
<td align="left" colspan="1" rowspan="1">ASD, intellectual disability, Juvenile myoclonic epilepsy</td>
<td align="left" colspan="1" rowspan="1">Girirajan et al. (<xref ref-type="ref" rid="brb3978-bib-0037">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1H</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1H subunit of T‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">16p13.3</td>
<td align="left" colspan="1" rowspan="1">Abundantly expressed in cerebellum and cerebral cortex, activates small depolarization and contributes to the oscillatory behavior in neurons</td>
<td align="left" colspan="1" rowspan="1">ASD, childhood absence epilepsy, idiopathic generalized epilepsy</td>
<td align="left" colspan="1" rowspan="1">Splawski et al. (<xref ref-type="ref" rid="brb3978-bib-0111">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA1I</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐1I subunit of T‐type Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">22q13.1</td>
<td align="left" colspan="1" rowspan="1">Modulates the Ca<sup>2+</sup> influx of T‐type channel in neurons and generates pacemaker activity</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>) and Hussman et al. (<xref ref-type="ref" rid="brb3978-bib-0045">2011</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA2D4</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐2/delta‐4 subunit of voltage‐gated Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">12p13.33</td>
<td align="left" colspan="1" rowspan="1">Modulates Ca<sup>2+</sup> influx and voltage‐gated channel properties</td>
<td align="left" colspan="1" rowspan="1">Retinal cone dystrophy 4, ASD (when gene deletion occurs along with CACNA1C)</td>
<td align="left" colspan="1" rowspan="1">Smith et al. (<xref ref-type="ref" rid="brb3978-bib-0109">2012</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNA2D3</italic>
</td>
<td align="left" colspan="1" rowspan="1">Alpha‐2/delta‐3 subunit of voltage‐gated Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">3p21.1–p14.3</td>
<td align="left" colspan="1" rowspan="1">Modulates Ca<sup>2+</sup> influx and voltage‐gated channel properties</td>
<td align="left" colspan="1" rowspan="1">ASD</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0013">2015</xref>) and Skafidas et al. (<xref ref-type="ref" rid="brb3978-bib-0108">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CACNB2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Beta‐2 subunit of voltage‐gated Ca<sup>2+</sup> channel</td>
<td align="left" colspan="1" rowspan="1">10p12.33–p12.31</td>
<td align="left" colspan="1" rowspan="1">Modulates the kinetics of L‐type calcium channel by increasing its activity</td>
<td align="left" colspan="1" rowspan="1">ASD, psychiatric diseases, Brugada syndrome</td>
<td align="left" colspan="1" rowspan="1">Breitenkamp et al. (<xref ref-type="ref" rid="brb3978-bib-0014">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SCN1A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Voltage‐regulated sodium channel type 1</td>
<td align="left" colspan="1" rowspan="1">2q24.3</td>
<td align="left" colspan="1" rowspan="1">Expressed in neurons and central and peripheral nervous system. Highly conserved through evolution. Controls channel gating and current</td>
<td align="left" colspan="1" rowspan="1">Inherited seizure disorder, Generalized Epilepsy with Febrile Seizures Plus (GEFS+), Juvenile myoclonic epilepsy, mental retardation, ASD</td>
<td align="left" colspan="1" rowspan="1">Craig et al. (<xref ref-type="ref" rid="brb3978-bib-0021">2012</xref>), O'Roak et al. (<xref ref-type="ref" rid="brb3978-bib-0084">2011</xref>), and Weiss et al. (<xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SCN2A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Voltage‐regulated sodium channel type 2</td>
<td align="left" colspan="1" rowspan="1">2q24.3</td>
<td align="left" colspan="1" rowspan="1">Expressed in neurons and central and peripheral nervous system. Controls channel gating and current</td>
<td align="left" colspan="1" rowspan="1">Early infantile epileptic, encephalopathy, benign familial infantile seizures, ASD</td>
<td align="left" colspan="1" rowspan="1">Celle et al. (<xref ref-type="ref" rid="brb3978-bib-0018">2013</xref>) and Weiss et al. (<xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SCN3A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Voltage‐regulated sodium channel type 3</td>
<td align="left" colspan="1" rowspan="1">2q24.3</td>
<td align="left" colspan="1" rowspan="1">Expressed in neurons and central and peripheral nervous system. Controls biophysical properties of the channel</td>
<td align="left" colspan="1" rowspan="1">Epilepsy, ASD</td>
<td align="left" colspan="1" rowspan="1">Celle et al. (<xref ref-type="ref" rid="brb3978-bib-0018">2013</xref>) and Weiss et al. (<xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SCN7A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Voltage‐regulated sodium channel type 7</td>
<td align="left" colspan="1" rowspan="1">2q24.3</td>
<td align="left" colspan="1" rowspan="1">Na<sup>+</sup>‐specific channel in excitable cells</td>
<td align="left" colspan="1" rowspan="1">ASD (homozygous deletion in autism)</td>
<td align="left" colspan="1" rowspan="1">Morrow et al. (<xref ref-type="ref" rid="brb3978-bib-0081">2008</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>SCN8A</italic>
</td>
<td align="left" colspan="1" rowspan="1">Voltage‐regulated sodium channel type 8</td>
<td align="left" colspan="1" rowspan="1">12q13.13</td>
<td align="left" colspan="1" rowspan="1">Alters the repetitive firing pattern of cerebellar Purkinje neurons</td>
<td align="left" colspan="1" rowspan="1">Cerebellar ataxia, epileptic encephalopathy early infantile, ASD</td>
<td align="left" colspan="1" rowspan="1">Weiss et al. (<xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNMA1</italic>
</td>
<td align="left" colspan="1" rowspan="1">Calcium‐activated large conductance potassium channel subfamily A</td>
<td align="left" colspan="1" rowspan="1">10q22.3</td>
<td align="left" colspan="1" rowspan="1">Synaptic protein regulator of neuronal excitability</td>
<td align="left" colspan="1" rowspan="1">Generalized epilepsy and paroxysmal dyskinesia (GEPD), ASD</td>
<td align="left" colspan="1" rowspan="1">Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNMB4</italic>
</td>
<td align="left" colspan="1" rowspan="1">BK channel beta subunit 4</td>
<td align="left" colspan="1" rowspan="1">12q15</td>
<td align="left" colspan="1" rowspan="1">Regulatory subunit of BK channel</td>
<td align="left" colspan="1" rowspan="1">ASD</td>
<td align="left" colspan="1" rowspan="1">Skafidas et al. (<xref ref-type="ref" rid="brb3978-bib-0108">2014</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNQ3</italic>
</td>
<td align="left" colspan="1" rowspan="1">Potassium voltage‐gated channel (M‐channel)</td>
<td align="left" colspan="1" rowspan="1">8q24.22</td>
<td align="left" colspan="1" rowspan="1">Modulates the kinetics of the channel</td>
<td align="left" colspan="1" rowspan="1">Rolandic epilepsy and idiopathic generalized epilepsy (IGE) including benign neonatal convulsions, ASD</td>
<td align="left" colspan="1" rowspan="1">Gilling et al. (<xref ref-type="ref" rid="brb3978-bib-0036">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>KCNQ5</italic>
</td>
<td align="left" colspan="1" rowspan="1">Potassium voltage‐gated channel (M‐channel)</td>
<td align="left" colspan="1" rowspan="1">6q13</td>
<td align="left" colspan="1" rowspan="1">Expressed in brain and muscle and implicated in slow activation of the channel. Interacts with KCNQ3</td>
<td align="left" colspan="1" rowspan="1">ASD</td>
<td align="left" colspan="1" rowspan="1">Gilling et al. (<xref ref-type="ref" rid="brb3978-bib-0036">2013</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>GRIK2</italic>
</td>
<td align="left" colspan="1" rowspan="1">Glutamate receptor ionotropic kainate 2</td>
<td align="left" colspan="1" rowspan="1">6q16.3</td>
<td align="left" colspan="1" rowspan="1">Glutamate receptors are the predominant excitatory neurotransmitter receptors in the central nervous system. Converts chemical signal to electrical impulse</td>
<td align="left" colspan="1" rowspan="1">Mental retardation, ASD</td>
<td align="left" colspan="1" rowspan="1">Ben‐Ari et al. (<xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>), Kang and Barnes (<xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>), and Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>GRIK3</italic>
</td>
<td align="left" colspan="1" rowspan="1">Glutamate receptor ionotropic kainate 3</td>
<td align="left" colspan="1" rowspan="1">1p34.3</td>
<td align="left" colspan="1" rowspan="1">Paralog of GRIK2</td>
<td align="left" colspan="1" rowspan="1">Schizophrenia, ASD</td>
<td align="left" colspan="1" rowspan="1">Ben‐Ari et al. (<xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>), Kang and Barnes, <xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>, and Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>CHRNA7</italic>
</td>
<td align="left" colspan="1" rowspan="1">Acetylcholine receptor, neuronal nicotinic, alpha‐7 subunit</td>
<td align="left" colspan="1" rowspan="1">15q13.3</td>
<td align="left" colspan="1" rowspan="1">Postsynaptic GABAergic interneuron activity. Mediates fast signal transmission at synapses</td>
<td align="left" colspan="1" rowspan="1">Schizophrenia, ASD</td>
<td align="left" colspan="1" rowspan="1">Ben‐Ari et al. (<xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>), Kang and Barnes (<xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>), and Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">
<italic>GABRG3</italic>
</td>
<td align="left" colspan="1" rowspan="1">GABA‐A gamma subunit of GABA receptor family</td>
<td align="left" colspan="1" rowspan="1">15q12</td>
<td align="left" colspan="1" rowspan="1">Conducts chloride ions upon activation leading to hyperpolarization. Causes inhibitory effect on neurotransmission</td>
<td align="left" colspan="1" rowspan="1">Schizophrenia, ASD</td>
<td align="left" colspan="1" rowspan="1">Ben‐Ari et al. (<xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>), Kang and Barnes, <xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>, and Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>)</td>
</tr>
</tbody>
</table>
<permissions>
<copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
</permissions>
</table-wrap>
<p>The importance of defective regulation of intracellular Ca<sup>2+</sup> in the pathophysiology of ASD is further supported by the association between genes that encode plasma membrane Ca<sup>2+</sup> pumps and ASD. In fact, three studies from different human populations reported an association between the <italic>ATP2B2</italic> gene coding for the plasma membrane Ca<sup>2+</sup> ATPase and ASD phenotypes (Yang et al., <xref ref-type="ref" rid="brb3978-bib-0128">2013</xref>). It should be noted that ASD‐associated genetic variations have been identified in genes encoding Ca<sup>2+</sup> channels and Ca<sup>2+</sup> transport pumps, as well as in genes encoding ion channels whose activities are under Ca<sup>2+</sup> modulation. To the best of our knowledge, until now, no association with other Ca<sup>2+</sup> channels such as ligand‐gated Ca<sup>2+</sup> channels (RyR, IP3R) has been found, hampering the exploration of novel cellular pathways.</p>
</sec>
<sec id="brb3978-sec-0012">
<label>2.2.2</label>
<title>Potassium (K<sup>+</sup>) channels in ASD</title>
<p>K<sup>+</sup> channels are located in membranes of excitable and non‐excitable cells and they assure K efflux out of cells. According to their structure and functions, K<sup>+</sup> channels are segregated into four categories: the voltage‐gated channels, inwardly rectifying (Kir), tandem pore domain (K2P), and the ligand‐gated (Kligand) channels (Kuang, Purhonen, &amp; Hebert, <xref ref-type="ref" rid="brb3978-bib-0056">2015</xref>). They all share a pore‐forming α subunit but different regulatory subunits are identified in each group. Ca<sup>2+</sup>‐activated potassium channels (BK<sub>Ca</sub>) are ligand‐gated K<sup>+</sup> channels that participate to several cell functions such as the regulation of hormone and neurotransmitter releases (Kuang et al., <xref ref-type="ref" rid="brb3978-bib-0056">2015</xref>). In fact, BK<sub>Ca</sub> are abundantly distributed throughout the brain and are mainly localized at presynaptic terminals, where they partake in the adjustment of synaptic transmission and neuronal excitability (Kuang et al., <xref ref-type="ref" rid="brb3978-bib-0056">2015</xref>; Laumonnier et al., <xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>). Laumonnier et al. (<xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>) observed a de novo balanced translocation of the 9q23/10q22 region that houses the α<sub>1</sub> subunit gene of BK<sub>Ca</sub> channel (<italic>KCNMA1)</italic> in patients with ASD. Electrophysiological experiments on lymphoblastoid cell lines derived from patients with ASD manifested a reduced activity of these channels. The authors also found a missense variation that alters a conserved domain of the channel in one patient with ASD (Laumonnier et al., <xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). Furthermore, a variation in the α<sub>1</sub> subunit of BK<sub>Ca</sub> channel (<italic>KCNMA1)</italic> has been implicated in generalized epilepsy and paroxysmal dyskinesia (Du et al., <xref ref-type="ref" rid="brb3978-bib-0030">2005</xref>). A novel missense variation (c.595A.T) in <italic>KCNB1</italic> gene that encodes K<sub>V</sub>2.1 voltage‐gated potassium channel was detected in a patient with ASD associated with intellectual disability and epilepsy. This variation causes the substitution of isoleucine to phenylalanine at codon 199 (p.I199F) leading to significant depolarizing shifts in the voltage dependence of activation and inactivation of the channel (Calhoun, Vanoye, Kok, George, &amp; Kearney, <xref ref-type="ref" rid="brb3978-bib-0016">2017</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). The regulatory β<sub>4</sub> subunit gene of BK<sub>Ca</sub> channel (<italic>KCNMB4</italic>) was classified as one of the three predictive genes in ASD as it was strongly associated with SNPs‐ASD‐associated in a large meta‐analysis study (Skafidas et al., <xref ref-type="ref" rid="brb3978-bib-0108">2014</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0003">3</xref>). On the other hand, a variation of <italic>KCNQ3</italic> gene mapped to chromosome 8q24, encoding the voltage‐gated potassium channel K<sub>v</sub>7.3, has been linked to epilepsy. This locus was found disrupted as a consequence of a de novo chromosomal translocation in one patient with ASD. In addition, three patients with ASD shared a missense variation in <italic>KCNQ3</italic>. This variation could be described as a loss of function as identified by electrophysiological recordings in <italic>Xenopus laevis</italic> oocytes (Gilling et al., <xref ref-type="ref" rid="brb3978-bib-0036">2013</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>).</p>
<p>These findings established a link between ASD and potassium channels and highlight their physiological importance in neuronal functions.</p>
</sec>
<sec id="brb3978-sec-0013">
<label>2.2.3</label>
<title>Sodium (Na<sup>+</sup>) Channels in ASD</title>
<p>Voltage‐gated Na<sup>+</sup> channels (Na<sub>v</sub>) are essential for the initiation and propagation of action potentials in neuronal cells, muscles, and heart tissues. Na<sub>V</sub> channels are heteromeric complexes comprised of an α subunit (pore‐forming) associated with one or more β regulatory subunits. We distinguish nine members of Na<sub>V</sub> channels (Na<sub>V</sub>1.1 to Na<sub>V</sub>1.9) that differ by their structure but also by their ligand‐specific binding sites (toxins, drugs) which has led to their classification as critical drug targets (Bagal, Marron, Owen, Storer, &amp; Swain, <xref ref-type="ref" rid="brb3978-bib-0005">2015</xref>).</p>
<p>Na<sub>v</sub> channels are primarily expressed in neurons and glial cells in the central and peripheral nervous system. Variations affecting the α subunit of Na<sup>+</sup> channels and their accessory β subunit are known to be responsible for Brugada syndrome, a cardiac disease (Weiss et al., <xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>). In addition, several variations in <italic>SCN1A</italic> and <italic>SCN2A</italic> that encode Na<sub>v</sub>1.1 and Na<sub>v</sub>1.2, respectively, are associated with childhood epilepsy and ASD (Weiss et al., <xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>). Variations in <italic>SCN1A</italic> and <italic>SCN2A</italic> were shown to cause familial hemiplegic migraine and to be implicated in severe seizure syndrome, epilepsy, and Dravet syndrome (Craig, de Menezes, &amp; Saneto, <xref ref-type="ref" rid="brb3978-bib-0021">2012</xref>; Weiss et al., <xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>). It was shown that variations in <italic>SCN2A</italic> affect the calmodulin‐binding site of the channel and reduce its affinity for Ca<sup>2+</sup>. This site is crucial for the binding between channel subunits and for connecting Na<sup>+</sup> channels to Ca<sup>2+</sup> signaling pathways (Weiss et al., <xref ref-type="ref" rid="brb3978-bib-0127">2003</xref>). Another study using array‐comparative genome hybridization identified a de novo deletion in a chromosome 2 region (2q24.2–q24.3) that contains <italic>SCN2A</italic> and <italic>SCN3A</italic> genes in a child with ASD (Celle, Cuoco, Porta, Gimelli, &amp; Tassano, <xref ref-type="ref" rid="brb3978-bib-0018">2013</xref>). These findings were also validated by whole‐exome sequencing study showing a significant association of <italic>SCN1A</italic> gene with the etiology of ASD (O'Roak et al., <xref ref-type="ref" rid="brb3978-bib-0086">2012</xref>; Sanders et al., <xref ref-type="ref" rid="brb3978-bib-0101">2012</xref>). Tavassoli et al. (<xref ref-type="ref" rid="brb3978-bib-0115">2014</xref>) using whole‐exome sequencing found a de novo splice site variation in <italic>SCN2A</italic> gene in one patient with ASD. This variation (c.476+1G&gt;A) that occurs at exon 4 of <italic>SCNA2A</italic> gene generates a truncated protein (Tavassoli et al., <xref ref-type="ref" rid="brb3978-bib-0115">2014</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). In addition, the α subunit 8 gene of a Na<sup>+</sup> channel was associated with ASD and identified by whole‐genome sequencing in a family with ASD. In fact, a de novo heterozygous missense variation was found in <italic>SCN8A</italic> gene (p.N1768D), which alters a conserved residue of the channel. The biophysical consequences of this variation are an increase in Na<sup>+</sup> current and partial channel inactivation (Veeramah et al., <xref ref-type="ref" rid="brb3978-bib-0122">2012</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0002">2</xref>). In a large study of consanguineous families with autism, a homozygous deletion of <italic>SCN7A</italic> gene was identified in one family, which is adjacent to <italic>SCN1A</italic> gene within the sodium channel gene cluster (<italic>SCN1A</italic>,<italic> SCN2A</italic>,<italic> SCN3A</italic>, and <italic>SCN9A</italic>) on chromosome 2 (Morrow et al., <xref ref-type="ref" rid="brb3978-bib-0081">2008</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0003">3</xref>).</p>
</sec>
<sec id="brb3978-sec-0014">
<label>2.2.4</label>
<title>Role of the ligand‐gated ion channels, GABA, glutamate, and cholinergic nicotinic receptors in ASD</title>
<p>Due to their crucial role in synaptic transmission, variations in GABA‐A receptors are implicated in several severe neurological and neuropsychiatric disorders (Kang &amp; Barnes, <xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>). Patients with ASD have been reported to carry rearrangements abnormalities in chromosome 15q11–13 known as the imprinted region of Angelman/Prader–Willi syndromes. This region houses a cluster of GABA receptor genes that include <italic>GABRA5</italic>,<italic> GABRG3,</italic> and <italic>GABRB3,</italic> as well as <italic>CHRNA7</italic> encoding the α7 subunit of the nicotinic acetylcholine receptor (nAChR; Hoppman‐Chaney, Wain, Seger, Superneau, &amp; Hodge, <xref ref-type="ref" rid="brb3978-bib-0043">2013</xref>). Moreover, polymorphisms in <italic>GABRA4</italic> have also been associated with autism. Two SNPs located within 15q12 region were significantly linked to ASD, suggesting that this particular region of <italic>GABRG3</italic> gene is associated with an increased risk for ASD (Ben‐Ari, Khalilov, Kahle, &amp; Cherubini, <xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>; Kang &amp; Barnes, <xref ref-type="ref" rid="brb3978-bib-0050">2013</xref>). ASD‐associated polymorphisms have been identified in both the <italic>GRIK2</italic> gene encoding the ionotropic glutamate receptor kainate 2 and the <italic>GRM5</italic> gene that encodes a metabotropic glutamate receptor. A recent study demonstrated a large spectrum of ASD phenotypes associated with the 15q11–13 microdeletions. This region includes the <italic>CHRNA7</italic> locus suggesting that <italic>CHRNA7</italic> is a critical gene in ASD (Kuang et al., <xref ref-type="ref" rid="brb3978-bib-0056">2015</xref>; Laumonnier et al., <xref ref-type="ref" rid="brb3978-bib-0061">2006</xref>).</p>
<p>GABA‐A receptors and Cl<sup>−</sup> concentration are important actors for the excitation/inhibition balance in neurons during neurogenesis. These two actors appear to be complementary in that the level of Cl<sup>−</sup> concentration is crucial for GABAergic signaling. The regulation of Cl<sup>−</sup> concentration in neurons is mediated by Cl<sup>−</sup> cotransporter (CCCs) proteins anchored into the plasma membrane. Their roles are to couple the transport of Na<sup>+</sup>, K<sup>+</sup>, and Cl<sup>−</sup> and are named Na/K‐Cl (NCC, NKCC1, and NKCC2) transporters. There are four different K‐CCCs (KCC1, KCC2, KCC3, and KCC4). In neurons, NKCC1 and KCC2 are the predominant Cl<sup>−</sup> exchangers (Ben‐Ari et al., <xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>). A variation in <italic>SLC12A2</italic> gene encoding NKCC1 was reported to be linked to schizophrenia. Functional experiments in <italic>Xenopus oocytes</italic> of this variation displayed an increased sensitivity to the NKCC blocker bumetanide. This evidence supports the hypothesis that NKCC1 activity is associated with schizophrenia and ASD because these two conditions share the same genetic background (Merner et al., <xref ref-type="ref" rid="brb3978-bib-0078">2016</xref>). In fact, it was demonstrated that patients with ASD present an elevated intracellular Cl<sup>−</sup> concentration in neurons, suggesting that defective excitability/inhibition balance could promote ASD due to an ineffective action of GABA leading to an abnormal chloride gradient (Ben‐Ari et al., <xref ref-type="ref" rid="brb3978-bib-0007">2012</xref>). Bumetanide blocks NKCC1 and decreases intracellular chloride concentration in neurons. A clinical study done on 60 children showed improvements in some ASD‐related clinical manifestations. Therefore, bumetanide is currently under investigation as a prospective drug by restoring the gradient and GABA inhibition and, thereby, considered as a potential ASD‐therapeutic agent (Lemonnier et al., <xref ref-type="ref" rid="brb3978-bib-0063">2012</xref>; Table <xref ref-type="table" rid="brb3978-tbl-0003">3</xref>).</p>
</sec>
</sec>
<sec id="brb3978-sec-0015">
<label>2.3</label>
<title>Ion channels and dysfunctional pathways in ASD</title>
<p>Several genes encoding proteins involved in cellular pathways have been found enriched in ASD. These proteins are essentially implicated in synapse regulation (chromatin remolding, synaptic functions and protein synthesis and degradation; De Rubeis et al., <xref ref-type="ref" rid="brb3978-bib-0023">2014</xref>; Hormozdiari, Penn, Borenstein, &amp; Eichler, <xref ref-type="ref" rid="brb3978-bib-0044">2015</xref>; Pinto et al., <xref ref-type="ref" rid="brb3978-bib-0092">2011</xref>; Ronemus, Iossifov, Levy, &amp; Wigler, <xref ref-type="ref" rid="brb3978-bib-0098">2014</xref>; Uddin et al., <xref ref-type="ref" rid="brb3978-bib-0118">2014</xref>; Voineagu et al., <xref ref-type="ref" rid="brb3978-bib-0123">2011</xref>).</p>
<p>Synaptic regulatory proteins mainly concern: glutamatergic (e.g., GRIN2B) and GABAergic (e.g., GABRA3 and GABRB3) neurotransmission, neuronal connection (e.g., CNTNAP2) and ion permeability (e.g., CACNA1, CACNA2D3, and SCN1A), as well as proteins directly involved in synapse formation such as neurexins (NRXNs) and neuroligins (NLGNs). Among the scaffold proteins, there are proteins involved in the regulation of cell adhesion molecules and neurotransmitter receptors density in the synapse. This is the example of SHANK family proteins that assemble into large molecular platforms interacting with glutamate receptors, ion channels, actin cytoskeleton‐associated proteins, and G protein‐coupled signaling pathways (Grabrucker, Schmeisser, Schoen, &amp; Boeckers, <xref ref-type="ref" rid="brb3978-bib-0038">2011</xref>). The SHANK proteins are associated with NMDA receptors via the guanylate kinase‐associated protein (GKAP)/postsynaptic density‐95 (PSD‐95) complex and with metabotropic glutamate receptors type 1 (mGluR1) <italic>via</italic> the neuronal scaffolding protein Homer1. In addition, SHANK proteins can bind to several actin‐regulatory molecules, such as cortactin (Durand et al., <xref ref-type="ref" rid="brb3978-bib-0033">2012</xref>). Mutations and CNVs (deletion and duplication) affecting <italic>SHANK</italic> genes have been associated with ASD. These variations resulted in actin accumulation in dendritic spines, which alters the development and the morphology of dendrites (Durand et al., <xref ref-type="ref" rid="brb3978-bib-0033">2012</xref>).</p>
<p>Furthermore, neuronal dysfunctions are due to the modifications in synthesis level of synaptic proteins caused by a defective mRNA regulation especially translation (Kelleher &amp; Bear, <xref ref-type="ref" rid="brb3978-bib-0051">2008</xref>). This mechanism is controlled by several genes in particular <italic>mTOR</italic> and <italic>FMR1</italic>. FMRP protein, encoded by <italic>FMR1</italic> gene, binds to 400 different mRNAs and represses their translation (Kelleher &amp; Bear, <xref ref-type="ref" rid="brb3978-bib-0051">2008</xref>). The loss of FMRP protein results in fragile X syndrome that is present in 5% in patients with ASD. This protein acts downstream of the Ras‐ERK signaling pathway <italic>via</italic> the complex FMRP–EIF4E–CYFIP1. This complex regulates the translation of more than 1,000 specific genes, many of which are ASD risk genes (De Rubeis et al., <xref ref-type="ref" rid="brb3978-bib-0023">2014</xref>). When CYFIP1 (cytoplasmic <italic>FMR1</italic> interacting protein 1) binds to FMRP protein, the complex inhibits directly the translation of mRNA or indirectly by preventing the ribosomal translocation on mRNA. It is interesting to note that the expression of FMRP is under the control of Ca<sup>2+</sup>/calmodulin‐dependent protein kinase 4 (CAMKIV). However, <italic>CYFIP1</italic> and <italic>CAMKIV</italic> have been described as susceptibility genes in ASD and together combined with an altered activity of FMPR enhances the ASD risk (Waltes et al., <xref ref-type="ref" rid="brb3978-bib-0125">2014</xref>).</p>
<p>Another pathway implicating calcium signaling and ASD is the Mammalian target of rapamycin (mTOR) pathway also known as the mechanistic target of rapamycin kinase. <italic>MTOR</italic> gene is a tumor suppressor that regulates calcium signaling and mitochondrial functions. mTOR controls cells growth, proliferation, and differentiation, involved in synapse plasticity, and inhibits autophagy by preventing protein degradation. Interestingly, mTOR is upstream regulated by several mediators such as growth factors signals (e.g., insulin) or in neurons by the brain‐derived neurotrophic factor (BDNF) through the phosphoinositide‐3‐kinase (PI3K) activation the protein kinase B (Akt) and Ras to the extracellular signal‐regulated kinase (Erk; Napoli et al., <xref ref-type="ref" rid="brb3978-bib-0082">2008</xref>; Schratt, Nigh, Chen, Hu, &amp; Greenberg, <xref ref-type="ref" rid="brb3978-bib-0105">2004</xref>).</p>
<p>Both Erk and Akt act on the tuberous sclerosis complex (TSC1 and TSC2) by phosphorylating TSC2 inducing its dissociation of TSC1. TSC1 and TSC2 proteins act like GTPase proteins and downregulate a small GTPase Rheb (Ras homolog enriched in brain) protein <italic>via</italic> GAP protein through a mechanism that remains unknown (Ma &amp; Blenis, <xref ref-type="ref" rid="brb3978-bib-0072">2009</xref>).</p>
<p>Rheb is a direct activator of mTOR complex by activating its regulatory associated protein (raptor; Ma &amp; Blenis, <xref ref-type="ref" rid="brb3978-bib-0072">2009</xref>). Once the mTOR complex is activated, it phosphorylates a series of protein such as the S6 kinase 1 (S6K1), the eukaryotic translation initiation factor 4E‐binding protein 1 (eIF‐4BP1), and the carbamoyl‐phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD). S6K1 and eIF‐4BP1 are essential for protein synthesis and polypeptide translation in ribosomes and cell proliferation, while CAD is a key player in pyrimidine synthesis and so nucleotide synthesis (Ma &amp; Blenis, <xref ref-type="ref" rid="brb3978-bib-0072">2009</xref>). In addition, the tuberous sclerosis complex can also be activated by AMPK, GSK3β, and p53 which leads the inhibition of mTOR pathway. Furthermore, variations in <italic>TSC1</italic> and <italic>TSC2</italic> genes have been associated with ASD (Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>). Also, variations in mTOR pathway repressors, such as for the neurofibromin 1 (NF1) gene <italic>NF1</italic>, cause neurofibromatosis type 1 syndrome as reported in 1% patients with ASD (Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>). The phosphatase and tension protein homolog (PTEN) is also known to downregulate mTOR pathway <italic>via</italic> both PI3K and AKT. Patients with ASD associated with cerebral malformation, like macrocephaly, have been found to carry variations in the <italic>PTEN</italic> gene in 7% of the cases (Devlin &amp; Scherer, <xref ref-type="ref" rid="brb3978-bib-0026">2012</xref>; McBride et al., <xref ref-type="ref" rid="brb3978-bib-0077">2010</xref>; Figure <xref ref-type="fig" rid="brb3978-fig-0001">1</xref>).</p>
<fig fig-type="Figure" id="brb3978-fig-0001" orientation="portrait" position="float" xml:lang="en">
<label>Figure 1</label>
<caption>
<p>Synaptic signaling pathways associated with autism spectrum disorder (<styled-content style="fixed-case">ASD</styled-content>). Alterations in the mechanistic target of rapamycin complex (<styled-content style="fixed-case">mTOR</styled-content>) are considered risk factors for <styled-content style="fixed-case">ASD</styled-content>. <styled-content style="fixed-case">mTOR</styled-content> is activated by Rheb‐<styled-content style="fixed-case">GTP</styled-content>. Upstream of Rheb is the tuberous sclerosis complex (<styled-content style="fixed-case">TSC</styled-content>1–<styled-content style="fixed-case">TSC</styled-content>2). <styled-content style="fixed-case">TSC</styled-content>2 contains a <styled-content style="fixed-case">GTP</styled-content>ase‐activating protein (<styled-content style="fixed-case">GAP</styled-content>) domain that converts Rheb from <styled-content style="fixed-case">GTP</styled-content>‐bound form to its inactive <styled-content style="fixed-case">GDP</styled-content>‐bound form. Several upstream signaling pathways ranging from <styled-content style="fixed-case">PI</styled-content>3K–<styled-content style="fixed-case">AKT</styled-content>, Ras–<styled-content style="fixed-case">ERK</styled-content>,<styled-content style="fixed-case"> LKB</styled-content>1–<styled-content style="fixed-case">AMPK</styled-content> and Wnt–<styled-content style="fixed-case">GSK</styled-content>3β pathways, positively or negatively regulate <styled-content style="fixed-case">mTOR</styled-content> signaling. (<styled-content style="fixed-case">AMPK</styled-content>,<styled-content style="fixed-case"> AMP</styled-content>‐activated protein kinase; <styled-content style="fixed-case">ERK</styled-content>, extracellular signal‐regulated kinase; <styled-content style="fixed-case">GSK</styled-content>3β, glycogen synthase kinase 3β; and <styled-content style="fixed-case">PI</styled-content>3K, phosphoinositide 3‐kinase). The <styled-content style="fixed-case">mTOR</styled-content> pathway is also regulated by the brain‐derived neurotrophic factor (<styled-content style="fixed-case">BDNF</styled-content>) which binds to the tropomyosin‐related kinase B (<styled-content style="fixed-case">TRKB</styled-content>). <styled-content style="fixed-case">BDNF</styled-content> plays a key role in the development and the plasticity of the central nervous system and it is considered a risk factor for <styled-content style="fixed-case">ASD</styled-content> because increased levels of <styled-content style="fixed-case">BDNF</styled-content> concentration have been observed in the serum and brain of patients with <styled-content style="fixed-case">ASD</styled-content>. <styled-content style="fixed-case">PI</styled-content>3K is also regulated by the synaptic protein <styled-content style="fixed-case">SHANK</styled-content>, which is associated with metabotropic glutamate receptors type 1 (<styled-content style="fixed-case">mG</styled-content>luR1) via the neuronal scaffolding protein <styled-content style="fixed-case">HOMER</styled-content>1. The <styled-content style="fixed-case">mTOR</styled-content> complex is a key modulator of protein synthesis by direct phosphorylation of 4E‐binding proteins (4E‐<styled-content style="fixed-case">BP</styled-content>s) and activation of the ribosomal subunit S6 kinase (S6Ks), which in turn phosphorylate translation initiation factors. Thus, <styled-content style="fixed-case">mTOR</styled-content> blocks the activation of cell autophagy and promotes cell proliferation, growth, and differentiation. The activity of the proteasome is also regulated by neuronal activity. The expression of <styled-content style="fixed-case">UBE</styled-content>3A is increased through the transcription factor <styled-content style="fixed-case">MEF</styled-content>2 and regulates the degradation of <styled-content style="fixed-case">ARC</styled-content> protein, which promotes the internalization of <styled-content style="fixed-case">AMPA</styled-content>‐R and regulates excitatory synapse development. Variations in the neuronal L‐type Ca<sup>2+</sup> channel α subunit <styled-content style="fixed-case">CACNA</styled-content>1C have been associated with Timothy syndrome and with <styled-content style="fixed-case">ASD</styled-content>. In addition, Ca<sup>2+</sup>/calmodulin‐dependent protein kinases are associated with components of the neuronal complex including the fragile X mental retardation protein (<styled-content style="fixed-case">FMRP</styled-content>) and its protein interaction <styled-content style="fixed-case">CYFIP</styled-content>1, which also consider candidate genes in <styled-content style="fixed-case">ASD</styled-content>. <styled-content style="fixed-case">UBE</styled-content>3A: ubiquitin–protein ligase E3A; <styled-content style="fixed-case">MEF</styled-content>2: myocyte‐specific enhancer factor 2; <styled-content style="fixed-case">ARC</styled-content>: activity‐regulated cytoskeleton‐associated protein; <styled-content style="fixed-case">AMPR</styled-content>:<styled-content style="fixed-case"> AMPA</styled-content> receptors; <styled-content style="fixed-case">CYFIP</styled-content>1: cytoplasmic <styled-content style="fixed-case">FMRP</styled-content>‐interacting protein 1</p>
</caption>
<graphic id="nlm-graphic-3" xlink:href="BRB3-8-e00978-g001"></graphic>
</fig>
<p>Besides protein synthesis and translation that have been shown to be implicated in the process of ASD, the mechanism of protein degradation was also studied in ASD. Genetic studies indicate that ubiquitin–proteasome system is necessary for normal human cognitive function by regulating the synapse assembly and elimination (Mabb &amp; Ehlers, <xref ref-type="ref" rid="brb3978-bib-0073">2010</xref>). The ubiquitin ligase enzyme Ube3A is a member of the E3 ubiquitin ligase family. The disruption of its activity leads to Angelman syndrome, while in turn the Angelman syndrome was described in ASD with CNVs and mutations in <italic>UBE3A</italic> gene (Greer et al., <xref ref-type="ref" rid="brb3978-bib-0039">2010</xref>). In Ube3A knockout mice, electrophysiological studies demonstrated an impaired long‐term potentiation (LTP) in the hippocampus, which suggest that alteration of Ube3A results in the loss of neuronal plasticity. In fact, Ube3A increases transcription through the myocyte enhancer factor 2 (MEF2) complex and regulates synapse function by ubiquitinating and degrading the synaptic protein Arc (activity‐regulated cytoskeleton‐associated protein). The role of Arc is to decrease long‐term potentiation by promoting the internalization of AMPA receptors, which are the mediators of the excitatory neurotransmission in the central nervous system (Greer et al., <xref ref-type="ref" rid="brb3978-bib-0039">2010</xref>). On another hand, a decrease in AMPAR expression at synapses has been observed in patients with fragile X syndrome. This decrease is due to excessive mGluR5 signaling resulting in an increased Arc translation and consequently excessive AMPA receptors internalization (Dolen &amp; Bear, <xref ref-type="ref" rid="brb3978-bib-0028">2008</xref>). In FMR1 knockout mice, injections of mGluR5 restore the AMPA receptors expression levels and prevent fragile X syndrome (Dolen et al., <xref ref-type="ref" rid="brb3978-bib-0029">2007</xref>).</p>
<p>Interestingly, it has been shown that an alteration of the inhibitory phosphorylation function of the Ca<sup>2+</sup>/calmodulin‐dependent protein kinase II (CamKII) is coupled to an increase in AMPA receptors expressed at the synapse (Rose, Jin, &amp; Craig, <xref ref-type="ref" rid="brb3978-bib-0099">2009</xref>). In addition, mutations affecting this critical site of CamKII were shown to prevent the behavioral deficit in <italic>UBE3A</italic> gene‐altered mice, suggesting that the Angelman syndrome is associated with a perturbation of CamKII functions (van Woerden et al., <xref ref-type="ref" rid="brb3978-bib-0120">2007</xref>; Figure <xref ref-type="fig" rid="brb3978-fig-0001">1</xref>).</p>
<p>Together, these studies emphasize the implication of ion channels in the pathophysiology of ASD and strengthen the hypothesis that pharmacological manipulation of ion channels function is a potential therapeutic target in ASD.</p>
</sec>
<sec id="brb3978-sec-0016">
<label>2.4</label>
<title>Ion channels and drug therapy in ASD</title>
<p>Ion channels have always been considered as powerful drug targets for the treatment of a wide range of pathologies owing to their crucial role as regulators of cell excitability (Kaczorowski, McManus, Priest, &amp; Garcia, <xref ref-type="ref" rid="brb3978-bib-0048">2008</xref>).</p>
<p>In 1884, cocaine was discovered as the first anesthetic drug (Vandam, <xref ref-type="ref" rid="brb3978-bib-0121">1987</xref>). Several decades later, cocaine was described as a Na<sup>+</sup> channel blocker (Kyle &amp; Ilyin, <xref ref-type="ref" rid="brb3978-bib-0057">2007</xref>; Vandam, <xref ref-type="ref" rid="brb3978-bib-0121">1987</xref>). This observation led the chemists to the production of novel analogs of cocaine, all classified under the term of “caine” and constituting a novel family of anesthetics (e.g., benzocaine, lidocaine; Casale, Symeonidou, &amp; Bartolo, <xref ref-type="ref" rid="brb3978-bib-0017">2017</xref>; Tremont‐Lukats, Megeff, &amp; Backonja, <xref ref-type="ref" rid="brb3978-bib-0117">2000</xref>). Thereafter, drug‐mediated modulation of Na<sup>+</sup> channel properties was found to have other therapeutic functions such as anticonvulsants and antidepressants (e.g., carbamazepine) used in the treatment of neuropathic pain (Tremont‐Lukats et al., <xref ref-type="ref" rid="brb3978-bib-0117">2000</xref>).</p>
<p>Valproic acid (VPA) is one of the most widely used anti‐epileptic drugs for the treatment of tonico‐clonic seizures that act by modulating Na<sup>+</sup> channel kinetics in neurons (Loscher, <xref ref-type="ref" rid="brb3978-bib-0070">2002</xref>). VPA is also used for the treatment of bipolar disorder, anxiety, and migraine (Loscher, <xref ref-type="ref" rid="brb3978-bib-0070">2002</xref>). Studies showed that the exposure to VPA during pregnancy induces neurobehavioral abnormalities similar to autism traits in both rodents and humans (Bertelsen et al., <xref ref-type="ref" rid="brb3978-bib-0008">2016</xref>; Choi et al., <xref ref-type="ref" rid="brb3978-bib-0019">2016</xref>; Mony, Lee, Dreyfus, DiCicco‐Bloom, &amp; Lee, <xref ref-type="ref" rid="brb3978-bib-0079">2016</xref>). In fact, VPA treatment of postnatal rats was shown to affect DNA synthesis and astrocyte proliferation and was associated with autistic behavior (Mony et al., <xref ref-type="ref" rid="brb3978-bib-0079">2016</xref>). A recent study showed that the phenotypic signs of ASD induced by VAP exposure in rats can be significantly improved or recovered by the administration of vitamin D in early stages of development (Du, Zhao, Duan, &amp; Li, <xref ref-type="ref" rid="brb3978-bib-0031">2017</xref>). In addition, it has been demonstrated that persistent Na<sup>+</sup> current is responsible for hypoxia in neurons leading to neuronal damages (Faustino &amp; Donnelly, <xref ref-type="ref" rid="brb3978-bib-0034">2006</xref>). In fact, the persistence of Na<sup>+</sup> currents leads to the increased activity of Na<sup>+</sup>/Ca<sup>2+</sup> exchangers in neurons, itself resulting in an increase in Ca<sup>2+</sup> cytoplasmic concentration (Faustino &amp; Donnelly, <xref ref-type="ref" rid="brb3978-bib-0034">2006</xref>). In order to correct this situation, it has been proposed that an increase in Na<sup>+</sup> influx into cells prevents trauma in the nervous system (Ates et al., <xref ref-type="ref" rid="brb3978-bib-0003">2007</xref>). Some Na<sup>+</sup> channel blockers (e.g., phenytoin, riluzole) showed neuroprotective activity in experimental spinal cord injury studies, in neurobehavioral studies and tissue recovery (Ates et al., <xref ref-type="ref" rid="brb3978-bib-0003">2007</xref>). It is important to mention that gabapentin, the first known drug in the treatment of neuropathic pain, specifically binds to the α2δ1 subunit of N‐type Ca<sup>2+</sup> channels and decreases the current (Zhu et al., <xref ref-type="ref" rid="brb3978-bib-0132">2017</xref>).</p>
<p>
<italic>N</italic>‐methyl‐<sc>d</sc>‐aspartate receptors (NMDAR) are well known to be associated with psychiatric disorders (Lakhan, Caro, &amp; Hadzimichalis, <xref ref-type="ref" rid="brb3978-bib-0060">2013</xref>). With no surprise, they were also linked to ASD risk (Lee, Choi, &amp; Kim, <xref ref-type="ref" rid="brb3978-bib-0062">2015</xref>). Their activation follows the binding of glutamate once the D‐serine or glycine co‐agonists engage the specific allosteric site of the receptor (Kim et al., <xref ref-type="ref" rid="brb3978-bib-0052">2005</xref>). These two ligands were used in a clinical study on patients with severe schizophrenia as antipsychotic agents and were able to correct some negative clinical aspects (Buchanan et al., <xref ref-type="ref" rid="brb3978-bib-0015">2007</xref>). In 1991, Haring et al. characterized an antibody, named B6B21, which showed a remarkable action in rat neurons by increasing long‐term potentiation in CA1 pyramidal cells. This antibody has a high binding affinity for NMDA receptors. As a matter of fact, the authors concluded that B6B21 acts in a similar way to glycine on the receptor (Haring, Stanton, Scheideler, &amp; Moskal, <xref ref-type="ref" rid="brb3978-bib-0040">1991</xref>). From B6B21, derived a family of small peptides called glyxines (Santini et al., <xref ref-type="ref" rid="brb3978-bib-0103">2014</xref>). One of these peptides, named GLYX‐13, was found to modulate NMDAR properties in a similar way to glycine. Treating ASD‐affected rats with of GLYX‐13 resulted in promising improvements of autistic signs. Thereafter, authors suggested that this antibody might be a potential treatment for patients affected by ASD (Santini et al., <xref ref-type="ref" rid="brb3978-bib-0103">2014</xref>). Moreover, <sc>d</sc>‐cycloserine, which is a partial NMDAR glycine agonist, is known to have effects on the behavioral deficits observed in autism and schizophrenia (Posey et al., <xref ref-type="ref" rid="brb3978-bib-0094">2004</xref>).</p>
<p>In a recent clinical trial carried out on 20 patients with autism, it has been shown that D‐cycloserine treatment alleviated the stereotyped behavior of these patients (Urbano et al., <xref ref-type="ref" rid="brb3978-bib-0119">2014</xref>). To go more into details, the administration of D‐cycloserine during 8 weeks with different dosages showed to be effective on ASD manifestations in these patients without showing any side effects (Urbano et al., <xref ref-type="ref" rid="brb3978-bib-0119">2014</xref>). Additional studies will be required to determine the therapeutic effect of this drug in ASD.</p>
<p>Concerning another therapeutic target, the implication of the acetylcholine receptor in ASD was demonstrated for the first time by the analysis of postmortem adult brains from patients that suffered ASD (Martin‐Ruiz et al., <xref ref-type="ref" rid="brb3978-bib-0075">2004</xref>). Analysis of mRNA levels by real‐time PCR in different brain tissues (cerebral cortex and cerebellum) showed a significant difference in the mRNA expression of several nicotinic acetylcholine receptor subunits (α3, α4, β2, and α7; Martin‐Ruiz et al., <xref ref-type="ref" rid="brb3978-bib-0075">2004</xref>). Thus, it was suggested that the loss of nAChR functionality in the brain could be responsible for the ASD phenotype (Martin‐Ruiz et al., <xref ref-type="ref" rid="brb3978-bib-0075">2004</xref>). Administration of acetylcholine receptor activator donepezil to an ASD‐affected boy proved beneficial for his cognitive skills after 6 weeks of treatment (Srivastava, Agarwal, &amp; Pundhir, <xref ref-type="ref" rid="brb3978-bib-0112">2011</xref>). A randomized double‐blind placebo‐controlled trial using glutamine in autistic children showed significant improvements for some ASD clinical signs (Ghaleiha et al., <xref ref-type="ref" rid="brb3978-bib-0035">2014</xref>). The α7 nicotinic acetylcholine receptor encoded by the <italic>CHRNA7</italic> gene has also been associated with ASD (Deutsch, Urbano, Burket, Herndon, &amp; Winebarger, <xref ref-type="ref" rid="brb3978-bib-0025">2011</xref>; Dineley, Pandya, &amp; Yakel, <xref ref-type="ref" rid="brb3978-bib-0027">2015</xref>). Due to their role and implication in several pathways (e.g., PI3K/Akt and Wnt), α7 nAChR is considered as powerful therapeutic candidates (Deutsch, Burket, Urbano, &amp; Benson, <xref ref-type="ref" rid="brb3978-bib-0024">2015</xref>).</p>
</sec>
</sec>
<sec id="brb3978-sec-0017">
<label>3</label>
<title>CONCLUSIONS</title>
<p>A number of genetic studies came to classify autism as the most genetically complex disease. However, only a few numbers of contributing alleles or co‐inherited alleles are found in ASD proving that additional epigenetic factors or environmental conditions may contribute to the clinical manifestation of this disorder. The several Mendelian pathologies associated with autism, for example, fragile X syndrome, provide the strongest argument highlighting the genetic basis of autism. These ASD‐associated pathologies are commonly confounded with autistic behaviors and therefore make it more difficult to carry out case studies that focus exclusively on ASD. The most promising genes identified so far include <italic>NLGN</italic>,<italic> SHANK,</italic> and <italic>SYNGAP1</italic>, which are involved in neurogenesis and synaptogenesis, suggesting that synaptic malfunction is a significant contributor to the etiology of ASD. Among ASD‐associated pathologies, Timothy syndrome linked channelopathies to ASD. In fact, recent studies implicate variations and mutations of genes encoding ion channels (Ca<sup>2+</sup>, K<sup>+</sup>, Na<sup>+</sup>, and Cl<sup>−</sup> channels) as a leading risk factor for ASD. Alterations of these channels highlight the complexity of the pathology that remains not fully understood. Interestingly, the wide implication of ion channels encoding genes in ASD may provide opportunities for pharmacological treatments of autistic patients because these channels represent powerful drug target. For instance, bumetanide is one of these potential therapeutic agents currently under evaluation. Some of ASD pathological conditions show an increase or decrease in ion channel activation/deactivation kinetics, suggesting that ion channel modulators may be therapeutic candidates for the treatment of ASD.</p>
<p>In conclusion, ASD is not a simple pathology and it is associated with a large spectrum of other diseases. Nevertheless, the genetic abnormalities so far indicate that defective neuronal function from the onset of neural development appears to be a leading cause in the manifestation of this syndrome.</p>
<p>Furthermore, defective regulation of ion flux through the cell membrane caused by altered kinetics of ion channels and transporters appears to cause an imbalance of excitation/inhibition in neural function that may lead to defective neuronal circuit formation and physiological response. Restoring ion dynamics to their physiological equilibrium may represent a promising therapeutic strategy for this devastating neurodevelopmental psychiatric disorder.</p>
</sec>
<sec id="brb3978-sec-0019">
<title>CONFLICT OF INTEREST</title>
<p>All authors state that they have no conflict of interests.</p>
</sec>
</body>
<back>
<ack id="brb3978-sec-0018">
<title>ACKNOWLEDGMENT</title>
<p>There are no acknowledgments to declare.</p>
</ack>
<ref-list content-type="cited-references" id="brb3978-bibl-0001">
<title>REFERENCES</title>
<ref id="brb3978-bib-0001">
<mixed-citation id="brb3978-cit-0001" publication-type="book">
<collab collab-type="authors">American Psychiatric Association</collab>
(<year>2013</year>). <source xml:lang="en"/>Diagnostic and statistical manual of mental disorders fifth edition (DSM‐5) (pp. <fpage>31</fpage>). <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>American Psychiatric Publisher</publisher-name>.</mixed-citation>
</ref>
<ref id="brb3978-bib-0002">
<mixed-citation id="brb3978-cit-0002" publication-type="journal">
<string-name>
<surname>Anney</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Klei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Pinto</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Regan</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Conroy</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Magalhaes</surname>, <given-names>T. R.</given-names>
</string-name>, … <string-name>
<surname>Hallmayer</surname>, <given-names>J.</given-names>
</string-name> (<year>2010</year>). <article-title>A genome‐wide scan for common alleles affecting risk for autism</article-title>. <source xml:lang="en"/>Human Molecular Genetics, <volume>19</volume>(<issue>20</issue>), <fpage>4072</fpage>–<lpage>4082</lpage>. <pub-id pub-id-type="doi">10.1093/hmg/ddq307</pub-id>
<pub-id pub-id-type="pmid">20663923</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0003">
<mixed-citation id="brb3978-cit-0003" publication-type="journal">
<string-name>
<surname>Ates</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Cayli</surname>, <given-names>S. R.</given-names>
</string-name>, <string-name>
<surname>Gurses</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Turkoz</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Tarim</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Cakir</surname>, <given-names>C. O.</given-names>
</string-name>, &amp; <string-name>
<surname>Kocak</surname>, <given-names>A.</given-names>
</string-name> (<year>2007</year>). <article-title>Comparative neuroprotective effect of sodium channel blockers after experimental spinal cord injury</article-title>. <source xml:lang="en"/>Journal of Clinical Neuroscience, <volume>14</volume>(<issue>7</issue>), <fpage>658</fpage>–<lpage>665</lpage>. <pub-id pub-id-type="doi">10.1016/j.jocn.2006.03.023</pub-id>
<pub-id pub-id-type="pmid">17532502</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0004">
<mixed-citation id="brb3978-cit-0004" publication-type="journal">
<string-name>
<surname>Badescu</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Filfan</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sandu</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Surugiu</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Ciobanu</surname>, <given-names>O.</given-names>
</string-name>, &amp; <string-name>
<surname>Popa‐Wagner</surname>, <given-names>A.</given-names>
</string-name> (<year>2016</year>). <article-title>Molecular mechanisms underlying neurodevelopmental disorders, ADHD and autism</article-title>. <source xml:lang="en"/>Romanian Journal of Morphology and Embryology, <volume>57</volume>(<issue>2</issue>), <fpage>361</fpage>–<lpage>366</lpage>.<pub-id pub-id-type="pmid">27516006</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0005">
<mixed-citation id="brb3978-cit-0005" publication-type="journal">
<string-name>
<surname>Bagal</surname>, <given-names>S. K.</given-names>
</string-name>, <string-name>
<surname>Marron</surname>, <given-names>B. E.</given-names>
</string-name>, <string-name>
<surname>Owen</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Storer</surname>, <given-names>R. I.</given-names>
</string-name>, &amp; <string-name>
<surname>Swain</surname>, <given-names>N. A.</given-names>
</string-name> (<year>2015</year>). <article-title>Voltage gated sodium channels as drug discovery targets</article-title>. <source xml:lang="en"/>Channels (Austin), <volume>9</volume>(<issue>6</issue>), <fpage>360</fpage>–<lpage>366</lpage>. <pub-id pub-id-type="doi">10.1080/19336950.2015.1079674</pub-id>
<pub-id pub-id-type="pmid">26646477</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0006">
<mixed-citation id="brb3978-cit-0006" publication-type="journal">
<string-name>
<surname>Barrett</surname>, <given-names>C. F.</given-names>
</string-name>, &amp; <string-name>
<surname>Tsien</surname>, <given-names>R. W.</given-names>
</string-name> (<year>2008</year>). <article-title>The Timothy syndrome mutation differentially affects voltage‐ and calcium‐dependent inactivation of CaV1.2L‐type calcium channels</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>105</volume>(<issue>6</issue>), <fpage>2157</fpage>–<lpage>2162</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0710501105</pub-id>
<pub-id pub-id-type="pmid">18250309</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0007">
<mixed-citation id="brb3978-cit-0007" publication-type="journal">
<string-name>
<surname>Ben‐Ari</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Khalilov</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Kahle</surname>, <given-names>K. T.</given-names>
</string-name>, &amp; <string-name>
<surname>Cherubini</surname>, <given-names>E.</given-names>
</string-name> (<year>2012</year>). <article-title>The GABA excitatory/inhibitory shift in brain maturation and neurological disorders</article-title>. <source xml:lang="en"/>The Neuroscientist, <volume>18</volume>(<issue>5</issue>), <fpage>467</fpage>–<lpage>486</lpage>. <pub-id pub-id-type="doi">10.1177/1073858412438697</pub-id>
<pub-id pub-id-type="pmid">22547529</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0008">
<mixed-citation id="brb3978-cit-0008" publication-type="journal">
<string-name>
<surname>Bertelsen</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Moller</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Folloni</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Drasbek</surname>, <given-names>K. R.</given-names>
</string-name>, <string-name>
<surname>Scheel‐Kruger</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Landau</surname>, <given-names>A. M.</given-names>
</string-name> (<year>2016</year>). <article-title>Increased GABAA receptor binding in amygdala after prenatal administration of valproic acid to rats</article-title>. <source xml:lang="en"/>Acta Neuropsychiatrica, <volume>29</volume>, <fpage>309</fpage>–<lpage>314</lpage>.<pub-id pub-id-type="pmid">27938419</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0009">
<mixed-citation id="brb3978-cit-0009" publication-type="journal">
<string-name>
<surname>Bidaud</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mezghrani</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Swayne</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Monteil</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Lory</surname>, <given-names>P.</given-names>
</string-name> (<year>2006</year>). <article-title>Voltage‐gated calcium channels in genetic diseases</article-title>. <source xml:lang="en"/>Biochimica et Biophysica Acta, <volume>1763</volume>(<issue>11</issue>), <fpage>1169</fpage>–<lpage>1174</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbamcr.2006.08.049</pub-id>
<pub-id pub-id-type="pmid">17034879</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0010">
<mixed-citation id="brb3978-cit-0010" publication-type="journal">
<string-name>
<surname>Boczek</surname>, <given-names>N. J.</given-names>
</string-name>, <string-name>
<surname>Miller</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Ye</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Nesterenko</surname>, <given-names>V. V.</given-names>
</string-name>, <string-name>
<surname>Tester</surname>, <given-names>D. J.</given-names>
</string-name>, <string-name>
<surname>Antzelevitch</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Ware</surname>, <given-names>S. M.</given-names>
</string-name> (<year>2015</year>). <article-title>Novel Timothy syndrome mutation leading to increase in CACNA1C window current</article-title>. <source xml:lang="en"/>Heart Rhythm, <volume>12</volume>(<issue>1</issue>), <fpage>211</fpage>–<lpage>219</lpage>. <pub-id pub-id-type="doi">10.1016/j.hrthm.2014.09.051</pub-id>
<pub-id pub-id-type="pmid">25260352</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0011">
<mixed-citation id="brb3978-cit-0011" publication-type="journal">
<string-name>
<surname>Bonora</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Graziano</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Minopoli</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Bacchelli</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Magini</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Diquigiovanni</surname>, <given-names>C.</given-names>
</string-name>, … <string-name>
<surname>Romeo</surname>, <given-names>G.</given-names>
</string-name> (<year>2014</year>). <article-title>Maternally inherited genetic variants of CADPS2 are present in autism spectrum disorders and intellectual disability patients</article-title>. <source xml:lang="en"/>EMBO Molecular Medicine, <volume>6</volume>(<issue>6</issue>), <fpage>795</fpage>–<lpage>809</lpage>.<pub-id pub-id-type="pmid">24737869</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0012">
<mixed-citation id="brb3978-cit-0012" publication-type="journal">
<string-name>
<surname>Bourgeron</surname>, <given-names>T.</given-names>
</string-name> (<year>2015</year>). <article-title>From the genetic architecture to synaptic plasticity in autism spectrum disorder</article-title>. <source xml:lang="en"/>Nature Reviews Neuroscience, <volume>16</volume>(<issue>9</issue>), <fpage>551</fpage>–<lpage>563</lpage>. <pub-id pub-id-type="doi">10.1038/nrn3992</pub-id>
<pub-id pub-id-type="pmid">26289574</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0013">
<mixed-citation id="brb3978-cit-0013" publication-type="journal">
<string-name>
<surname>Breitenkamp</surname>, <given-names>A. F.</given-names>
</string-name>, <string-name>
<surname>Matthes</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Herzig</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>Voltage‐gated calcium channels and autism spectrum disorders</article-title>. <source xml:lang="en"/>Current Molecular Pharmacology, <volume>8</volume>(<issue>2</issue>), <fpage>123</fpage>–<lpage>132</lpage>. <pub-id pub-id-type="doi">10.2174/1874467208666150507105235</pub-id>
<pub-id pub-id-type="pmid">25966693</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0014">
<mixed-citation id="brb3978-cit-0014" publication-type="journal">
<string-name>
<surname>Breitenkamp</surname>, <given-names>A. F.</given-names>
</string-name>, <string-name>
<surname>Matthes</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nass</surname>, <given-names>R. D.</given-names>
</string-name>, <string-name>
<surname>Sinzig</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lehmkuhl</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Nurnberg</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Herzig</surname>, <given-names>S.</given-names>
</string-name> (<year>2014</year>). <article-title>Rare mutations of CACNB2 found in autism spectrum disease‐affected families alter calcium channel function</article-title>. <source xml:lang="en"/>PLoS One, <volume>9</volume>(<issue>4</issue>), <fpage>e95579</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0095579</pub-id>
<pub-id pub-id-type="pmid">24752249</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0015">
<mixed-citation id="brb3978-cit-0015" publication-type="journal">
<string-name>
<surname>Buchanan</surname>, <given-names>R. W.</given-names>
</string-name>, <string-name>
<surname>Javitt</surname>, <given-names>D. C.</given-names>
</string-name>, <string-name>
<surname>Marder</surname>, <given-names>S. R.</given-names>
</string-name>, <string-name>
<surname>Schooler</surname>, <given-names>N. R.</given-names>
</string-name>, <string-name>
<surname>Gold</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>McMahon</surname>, <given-names>R. P.</given-names>
</string-name>, … <string-name>
<surname>Carpenter</surname>, <given-names>W. T.</given-names>
</string-name> (<year>2007</year>). <article-title>The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The efficacy of glutamatergic agents for negative symptoms and cognitive impairments</article-title>. <source xml:lang="en"/>The American Journal of Psychiatry, <volume>164</volume>(<issue>10</issue>), <fpage>1593</fpage>–<lpage>1602</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2007.06081358</pub-id>
<pub-id pub-id-type="pmid">17898352</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0016">
<mixed-citation id="brb3978-cit-0016" publication-type="journal">
<string-name>
<surname>Calhoun</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Vanoye</surname>, <given-names>C. G.</given-names>
</string-name>, <string-name>
<surname>Kok</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>George</surname>
<suffix>Jr</suffix>, <given-names>A. L.</given-names>
</string-name>, &amp; <string-name>
<surname>Kearney</surname>, <given-names>J. A.</given-names>
</string-name> (<year>2017</year>). <article-title>Characterization of a KCNB1 variant associated with autism, intellectual disability, and epilepsy</article-title>. <source xml:lang="en"/>Neurology Genetics, <volume>3</volume>(<issue>6</issue>), <fpage>e198</fpage>
<pub-id pub-id-type="doi">10.1212/NXG.0000000000000198</pub-id>
<pub-id pub-id-type="pmid">29264390</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0017">
<mixed-citation id="brb3978-cit-0017" publication-type="journal">
<string-name>
<surname>Casale</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Symeonidou</surname>, <given-names>Z.</given-names>
</string-name>, &amp; <string-name>
<surname>Bartolo</surname>, <given-names>M.</given-names>
</string-name> (<year>2017</year>). <article-title>Topical treatments for localized neuropathic pain</article-title>. <source xml:lang="en"/>Current Pain and Headache Reports, <volume>21</volume>(<issue>3</issue>), <fpage>15</fpage>
<pub-id pub-id-type="doi">10.1007/s11916-017-0615-y</pub-id>
<pub-id pub-id-type="pmid">28271334</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0018">
<mixed-citation id="brb3978-cit-0018" publication-type="journal">
<string-name>
<surname>Celle</surname>, <given-names>M. E.</given-names>
</string-name>, <string-name>
<surname>Cuoco</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Porta</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Gimelli</surname>, <given-names>G.</given-names>
</string-name>, &amp; <string-name>
<surname>Tassano</surname>, <given-names>E.</given-names>
</string-name> (<year>2013</year>). <article-title>Interstitial 2q24.3 deletion including SCN2A and SCN3A genes in a patient with autistic features, psychomotor delay, microcephaly and no history of seizures</article-title>. <source xml:lang="en"/>Gene, <volume>532</volume>(<issue>2</issue>), <fpage>294</fpage>–<lpage>296</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2013.09.073</pub-id>
<pub-id pub-id-type="pmid">24080482</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0019">
<mixed-citation id="brb3978-cit-0019" publication-type="journal">
<string-name>
<surname>Choi</surname>, <given-names>C. S.</given-names>
</string-name>, <string-name>
<surname>Gonzales</surname>, <given-names>E. L.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>K. C.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>S. M.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>J. W.</given-names>
</string-name>, <string-name>
<surname>Mabunga</surname>, <given-names>D. F.</given-names>
</string-name>, … <string-name>
<surname>Shin</surname>, <given-names>C. Y.</given-names>
</string-name> (<year>2016</year>). <article-title>The transgenerational inheritance of autism‐like phenotypes in mice exposed to valproic acid during pregnancy</article-title>. <source xml:lang="en"/>Scientific Reports, <volume>6</volume>, <fpage>36250</fpage>
<pub-id pub-id-type="doi">10.1038/srep36250</pub-id>
<pub-id pub-id-type="pmid">27819277</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0020">
<mixed-citation id="brb3978-cit-0020" publication-type="journal">
<string-name>
<surname>Cotney</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Muhle</surname>, <given-names>R. A.</given-names>
</string-name>, <string-name>
<surname>Sanders</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Willsey</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Niu</surname>, <given-names>W.</given-names>
</string-name>, … <string-name>
<surname>Noonan</surname>, <given-names>J. P.</given-names>
</string-name> (<year>2015</year>). <article-title>The autism‐associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment</article-title>. <source xml:lang="en"/>Nature Communications, <volume>6</volume>, <fpage>6404</fpage>
<pub-id pub-id-type="doi">10.1038/ncomms7404</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0021">
<mixed-citation id="brb3978-cit-0021" publication-type="journal">
<string-name>
<surname>Craig</surname>, <given-names>A. K.</given-names>
</string-name>, <string-name>
<surname>de Menezes</surname>, <given-names>M. S.</given-names>
</string-name>, &amp; <string-name>
<surname>Saneto</surname>, <given-names>R. P.</given-names>
</string-name> (<year>2012</year>). <article-title>Dravet syndrome: Patients with co‐morbid SCN1A gene mutations and mitochondrial electron transport chain defects</article-title>. <source xml:lang="en"/>Seizure, <volume>21</volume>(<issue>1</issue>), <fpage>17</fpage>–<lpage>20</lpage>. <pub-id pub-id-type="doi">10.1016/j.seizure.2011.08.010</pub-id>
<pub-id pub-id-type="pmid">21906962</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0022">
<mixed-citation id="brb3978-cit-0022" publication-type="journal">
<collab collab-type="authors">Cross‐Disorder Group of the Psychiatric Genomics Consortium</collab>
(<year>2013</year>). <article-title>Identification of risk loci with shared effects on five major psychiatric disorders: A genome‐wide analysis</article-title>. <source xml:lang="en"/>Lancet, <volume>381</volume>(<issue>9875</issue>), <fpage>1371</fpage>–<lpage>1379</lpage>.<pub-id pub-id-type="pmid">23453885</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0023">
<mixed-citation id="brb3978-cit-0023" publication-type="journal">
<string-name>
<surname>De Rubeis</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>He</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Goldberg</surname>, <given-names>A. P.</given-names>
</string-name>, <string-name>
<surname>Poultney</surname>, <given-names>C. S.</given-names>
</string-name>, <string-name>
<surname>Samocha</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Cicek</surname>, <given-names>A. E.</given-names>
</string-name>, … <string-name>
<surname>Buxbaum</surname>, <given-names>J. D.</given-names>
</string-name> (<year>2014</year>). <article-title>Synaptic, transcriptional and chromatin genes disrupted in autism</article-title>. <source xml:lang="en"/>Nature, <volume>515</volume>(<issue>7526</issue>), <fpage>209</fpage>–<lpage>215</lpage>. <pub-id pub-id-type="doi">10.1038/nature13772</pub-id>
<pub-id pub-id-type="pmid">25363760</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0024">
<mixed-citation id="brb3978-cit-0024" publication-type="journal">
<string-name>
<surname>Deutsch</surname>, <given-names>S. I.</given-names>
</string-name>, <string-name>
<surname>Burket</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Urbano</surname>, <given-names>M. R.</given-names>
</string-name>, &amp; <string-name>
<surname>Benson</surname>, <given-names>A. D.</given-names>
</string-name> (<year>2015</year>). <article-title>The alpha7 nicotinic acetylcholine receptor: A mediator of pathogenesis and therapeutic target in autism spectrum disorders and Down syndrome</article-title>. <source xml:lang="en"/>Biochemical Pharmacology, <volume>97</volume>(<issue>4</issue>), <fpage>363</fpage>–<lpage>377</lpage>. <pub-id pub-id-type="doi">10.1016/j.bcp.2015.06.005</pub-id>
<pub-id pub-id-type="pmid">26074265</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0025">
<mixed-citation id="brb3978-cit-0025" publication-type="journal">
<string-name>
<surname>Deutsch</surname>, <given-names>S. I.</given-names>
</string-name>, <string-name>
<surname>Urbano</surname>, <given-names>M. R.</given-names>
</string-name>, <string-name>
<surname>Burket</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Herndon</surname>, <given-names>A. L.</given-names>
</string-name>, &amp; <string-name>
<surname>Winebarger</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2011</year>). <article-title>Pharmacotherapeutic implications of the association between genomic instability at chromosome 15q13.3 and autism spectrum disorders</article-title>. <source xml:lang="en"/>Clinical Neuropharmacology, <volume>34</volume>(<issue>6</issue>), <fpage>203</fpage>–<lpage>205</lpage>. <pub-id pub-id-type="doi">10.1097/WNF.0b013e31823a1247</pub-id>
<pub-id pub-id-type="pmid">22094647</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0026">
<mixed-citation id="brb3978-cit-0026" publication-type="journal">
<string-name>
<surname>Devlin</surname>, <given-names>B.</given-names>
</string-name>, &amp; <string-name>
<surname>Scherer</surname>, <given-names>S. W.</given-names>
</string-name> (<year>2012</year>). <article-title>Genetic architecture in autism spectrum disorder</article-title>. <source xml:lang="en"/>Current Opinion in Genetics &amp; Development, <volume>22</volume>(<issue>3</issue>), <fpage>229</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.gde.2012.03.002</pub-id>
<pub-id pub-id-type="pmid">22463983</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0027">
<mixed-citation id="brb3978-cit-0027" publication-type="journal">
<string-name>
<surname>Dineley</surname>, <given-names>K. T.</given-names>
</string-name>, <string-name>
<surname>Pandya</surname>, <given-names>A. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Yakel</surname>, <given-names>J. L.</given-names>
</string-name> (<year>2015</year>). <article-title>Nicotinic ACh receptors as therapeutic targets in CNS disorders</article-title>. <source xml:lang="en"/>Trends in Pharmacological Sciences, <volume>36</volume>(<issue>2</issue>), <fpage>96</fpage>–<lpage>108</lpage>. <pub-id pub-id-type="doi">10.1016/j.tips.2014.12.002</pub-id>
<pub-id pub-id-type="pmid">25639674</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0028">
<mixed-citation id="brb3978-cit-0028" publication-type="journal">
<string-name>
<surname>Dolen</surname>, <given-names>G.</given-names>
</string-name>, &amp; <string-name>
<surname>Bear</surname>, <given-names>M. F.</given-names>
</string-name> (<year>2008</year>). <article-title>Role for metabotropic glutamate receptor 5 (mGluR5) in the pathogenesis of fragile X syndrome</article-title>. <source xml:lang="en"/>The Journal of Physiology, <volume>586</volume>(<issue>6</issue>), <fpage>1503</fpage>–<lpage>1508</lpage>. <pub-id pub-id-type="doi">10.1113/jphysiol.2008.150722</pub-id>
<pub-id pub-id-type="pmid">18202092</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0029">
<mixed-citation id="brb3978-cit-0029" publication-type="journal">
<string-name>
<surname>Dolen</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Osterweil</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Rao</surname>, <given-names>B. S.</given-names>
</string-name>, <string-name>
<surname>Smith</surname>, <given-names>G. B.</given-names>
</string-name>, <string-name>
<surname>Auerbach</surname>, <given-names>B. D.</given-names>
</string-name>, <string-name>
<surname>Chattarji</surname>, <given-names>S.</given-names>
</string-name>, &amp; <string-name>
<surname>Bear</surname>, <given-names>M. F.</given-names>
</string-name> (<year>2007</year>). <article-title>Correction of fragile X syndrome in mice</article-title>. <source xml:lang="en"/>Neuron, <volume>56</volume>(<issue>6</issue>), <fpage>955</fpage>–<lpage>962</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2007.12.001</pub-id>
<pub-id pub-id-type="pmid">18093519</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0030">
<mixed-citation id="brb3978-cit-0030" publication-type="journal">
<string-name>
<surname>Du</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Bautista</surname>, <given-names>J. F.</given-names>
</string-name>, <string-name>
<surname>Yang</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Diez‐Sampedro</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>You</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name>, … <string-name>
<surname>Wang</surname>, <given-names>Q. K.</given-names>
</string-name> (<year>2005</year>). <article-title>Calcium‐sensitive potassium channelopathy in human epilepsy and paroxysmal movement disorder</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>37</volume>(<issue>7</issue>), <fpage>733</fpage>–<lpage>738</lpage>. <pub-id pub-id-type="doi">10.1038/ng1585</pub-id>
<pub-id pub-id-type="pmid">15937479</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0031">
<mixed-citation id="brb3978-cit-0031" publication-type="journal">
<string-name>
<surname>Du</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Duan</surname>, <given-names>Z.</given-names>
</string-name>, &amp; <string-name>
<surname>Li</surname>, <given-names>F.</given-names>
</string-name> (<year>2017</year>). <article-title>Behavioral improvements in a valproic acid rat model of autism following vitamin D supplementation</article-title>. <source xml:lang="en"/>Psychiatry Research, <volume>253</volume>, <fpage>28</fpage>–<lpage>32</lpage>. <pub-id pub-id-type="doi">10.1016/j.psychres.2017.03.003</pub-id>
<pub-id pub-id-type="pmid">28324861</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0032">
<mixed-citation id="brb3978-cit-0032" publication-type="journal">
<string-name>
<surname>Durand</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Betancur</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Boeckers</surname>, <given-names>T. M.</given-names>
</string-name>, <string-name>
<surname>Bockmann</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Chaste</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Fauchereau</surname>, <given-names>F.</given-names>
</string-name>, … <string-name>
<surname>Bourgeron</surname>, <given-names>T.</given-names>
</string-name> (<year>2007</year>). <article-title>Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>39</volume>(<issue>1</issue>), <fpage>25</fpage>–<lpage>27</lpage>. <pub-id pub-id-type="doi">10.1038/ng1933</pub-id>
<pub-id pub-id-type="pmid">17173049</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0033">
<mixed-citation id="brb3978-cit-0033" publication-type="journal">
<string-name>
<surname>Durand</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Perroy</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Loll</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Perrais</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fagni</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Bourgeron</surname>, <given-names>T.</given-names>
</string-name>, … <string-name>
<surname>Sans</surname>, <given-names>N.</given-names>
</string-name> (<year>2012</year>). <article-title>SHANK3 mutations identified in autism lead to modification of dendritic spine morphology via an actin‐dependent mechanism</article-title>. <source xml:lang="en"/>Molecular Psychiatry, <volume>17</volume>(<issue>1</issue>), <fpage>71</fpage>–<lpage>84</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2011.57</pub-id>
<pub-id pub-id-type="pmid">21606927</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0034">
<mixed-citation id="brb3978-cit-0034" publication-type="journal">
<string-name>
<surname>Faustino</surname>, <given-names>E. V.</given-names>
</string-name>, &amp; <string-name>
<surname>Donnelly</surname>, <given-names>D. F.</given-names>
</string-name> (<year>2006</year>). <article-title>An important functional role of persistent Na<sup>+</sup> current in carotid body hypoxia transduction</article-title>. <source xml:lang="en"/>Journal of Applied Physiology, <volume>101</volume>(<issue>4</issue>), <fpage>1076</fpage>–<lpage>1084</lpage>. <pub-id pub-id-type="doi">10.1152/japplphysiol.00090.2006</pub-id>
<pub-id pub-id-type="pmid">16778007</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0035">
<mixed-citation id="brb3978-cit-0035" publication-type="journal">
<string-name>
<surname>Ghaleiha</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Ghyasvand</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Mohammadi</surname>, <given-names>M. R.</given-names>
</string-name>, <string-name>
<surname>Farokhnia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yadegari</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Tabrizi</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Akhondzadeh</surname>, <given-names>S.</given-names>
</string-name> (<year>2014</year>). <article-title>Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double‐blind, placebo‐controlled trial</article-title>. <source xml:lang="en"/>Journal of Psychopharmacology, <volume>28</volume>(<issue>7</issue>), <fpage>677</fpage>–<lpage>685</lpage>. <pub-id pub-id-type="doi">10.1177/0269881113508830</pub-id>
<pub-id pub-id-type="pmid">24132248</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0036">
<mixed-citation id="brb3978-cit-0036" publication-type="journal">
<string-name>
<surname>Gilling</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Rasmussen</surname>, <given-names>H. B.</given-names>
</string-name>, <string-name>
<surname>Calloe</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Sequeira</surname>, <given-names>A. F.</given-names>
</string-name>, <string-name>
<surname>Baretto</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Oliveira</surname>, <given-names>G.</given-names>
</string-name>, … <string-name>
<surname>Tommerup</surname>, <given-names>N.</given-names>
</string-name> (<year>2013</year>). <article-title>Dysfunction of the heteromeric KV7.3/KV7.5 potassium channel is associated with autism spectrum disorders</article-title>. <source xml:lang="en"/>Frontiers in Genetics, <volume>4</volume>, <fpage>54</fpage>.<pub-id pub-id-type="pmid">23596459</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0037">
<mixed-citation id="brb3978-cit-0037" publication-type="journal">
<string-name>
<surname>Girirajan</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Dennis</surname>, <given-names>M. Y.</given-names>
</string-name>, <string-name>
<surname>Baker</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Malig</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Coe</surname>, <given-names>B. P.</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>, <given-names>C. D.</given-names>
</string-name>, … <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2013</year>). <article-title>Refinement and discovery of new hotspots of copy‐number variation associated with autism spectrum disorder</article-title>. <source xml:lang="en"/>American Journal of Human Genetics, <volume>92</volume>(<issue>2</issue>), <fpage>221</fpage>–<lpage>237</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.12.016</pub-id>
<pub-id pub-id-type="pmid">23375656</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0038">
<mixed-citation id="brb3978-cit-0038" publication-type="journal">
<string-name>
<surname>Grabrucker</surname>, <given-names>A. M.</given-names>
</string-name>, <string-name>
<surname>Schmeisser</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Schoen</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Boeckers</surname>, <given-names>T. M.</given-names>
</string-name> (<year>2011</year>). <article-title>Postsynaptic ProSAP/Shank scaffolds in the cross‐hair of synaptopathies</article-title>. <source xml:lang="en"/>Trends in Cell Biology, <volume>21</volume>(<issue>10</issue>), <fpage>594</fpage>–<lpage>603</lpage>. <pub-id pub-id-type="doi">10.1016/j.tcb.2011.07.003</pub-id>
<pub-id pub-id-type="pmid">21840719</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0039">
<mixed-citation id="brb3978-cit-0039" publication-type="journal">
<string-name>
<surname>Greer</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Hanayama</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Bloodgood</surname>, <given-names>B. L.</given-names>
</string-name>, <string-name>
<surname>Mardinly</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<surname>Lipton</surname>, <given-names>D. M.</given-names>
</string-name>, <string-name>
<surname>Flavell</surname>, <given-names>S. W.</given-names>
</string-name>, &amp; <string-name>
<surname>Greenberg</surname>, <given-names>M. E.</given-names>
</string-name> (<year>2010</year>). <article-title>The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc</article-title>. <source xml:lang="en"/>Cell, <volume>140</volume>(<issue>5</issue>), <fpage>704</fpage>–<lpage>716</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2010.01.026</pub-id>
<pub-id pub-id-type="pmid">20211139</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0040">
<mixed-citation id="brb3978-cit-0040" publication-type="journal">
<string-name>
<surname>Haring</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Stanton</surname>, <given-names>P. K.</given-names>
</string-name>, <string-name>
<surname>Scheideler</surname>, <given-names>M. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Moskal</surname>, <given-names>J. R.</given-names>
</string-name> (<year>1991</year>). <article-title>Glycine‐like modulation of N‐methyl‐D‐aspartate receptors by a monoclonal antibody that enhances long‐term potentiation</article-title>. <source xml:lang="en"/>Journal of Neurochemistry, <volume>57</volume>(<issue>1</issue>), <fpage>323</fpage>–<lpage>332</lpage>. <pub-id pub-id-type="doi">10.1111/j.1471-4159.1991.tb02131.x</pub-id>
<pub-id pub-id-type="pmid">1828831</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0041">
<mixed-citation id="brb3978-cit-0041" publication-type="journal">
<string-name>
<surname>Hemara‐Wahanui</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Berjukow</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hope</surname>, <given-names>C. I.</given-names>
</string-name>, <string-name>
<surname>Dearden</surname>, <given-names>P. K.</given-names>
</string-name>, <string-name>
<surname>Wu</surname>, <given-names>S. B.</given-names>
</string-name>, <string-name>
<surname>Wilson‐Wheeler</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Maw</surname>, <given-names>M. A.</given-names>
</string-name> (<year>2005</year>). <article-title>A CACNA1F mutation identified in an X‐linked retinal disorder shifts the voltage dependence of Cav1.4 channel activation</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>102</volume>(<issue>21</issue>), <fpage>7553</fpage>–<lpage>7558</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0501907102</pub-id>
<pub-id pub-id-type="pmid">15897456</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0042">
<mixed-citation id="brb3978-cit-0042" publication-type="journal">
<string-name>
<surname>Heyes</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Pratt</surname>, <given-names>W. S.</given-names>
</string-name>, <string-name>
<surname>Rees</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Dahimene</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Ferron</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Owen</surname>, <given-names>M. J.</given-names>
</string-name>, &amp; <string-name>
<surname>Dolphin</surname>, <given-names>A. C.</given-names>
</string-name> (<year>2015</year>). <article-title>Genetic disruption of voltage‐gated calcium channels in psychiatric and neurological disorders</article-title>. <source xml:lang="en"/>Progress in Neurobiology, <volume>134</volume>, <fpage>36</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.pneurobio.2015.09.002</pub-id>
<pub-id pub-id-type="pmid">26386135</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0043">
<mixed-citation id="brb3978-cit-0043" publication-type="journal">
<string-name>
<surname>Hoppman‐Chaney</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Wain</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Seger</surname>, <given-names>P. R.</given-names>
</string-name>, <string-name>
<surname>Superneau</surname>, <given-names>D. W.</given-names>
</string-name>, &amp; <string-name>
<surname>Hodge</surname>, <given-names>J. C.</given-names>
</string-name> (<year>2013</year>). <article-title>Identification of single gene deletions at 15q13.3: Further evidence that CHRNA7 causes the 15q13.3 microdeletion syndrome phenotype</article-title>. <source xml:lang="en"/>Clinical Genetics, <volume>83</volume>(<issue>4</issue>), <fpage>345</fpage>–<lpage>351</lpage>. <pub-id pub-id-type="doi">10.1111/j.1399-0004.2012.01925.x</pub-id>
<pub-id pub-id-type="pmid">22775350</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0044">
<mixed-citation id="brb3978-cit-0044" publication-type="journal">
<string-name>
<surname>Hormozdiari</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Penn</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Borenstein</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2015</year>). <article-title>The discovery of integrated gene networks for autism and related disorders</article-title>. <source xml:lang="en"/>Genome Research, <volume>25</volume>(<issue>1</issue>), <fpage>142</fpage>–<lpage>154</lpage>. <pub-id pub-id-type="doi">10.1101/gr.178855.114</pub-id>
<pub-id pub-id-type="pmid">25378250</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0045">
<mixed-citation id="brb3978-cit-0045" publication-type="journal">
<string-name>
<surname>Hussman</surname>, <given-names>J. P.</given-names>
</string-name>, <string-name>
<surname>Chung</surname>, <given-names>R. H.</given-names>
</string-name>, <string-name>
<surname>Griswold</surname>, <given-names>A. J.</given-names>
</string-name>, <string-name>
<surname>Jaworski</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Salyakina</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ma</surname>, <given-names>D.</given-names>
</string-name>, … <string-name>
<surname>Pericak‐Vance</surname>, <given-names>M. A.</given-names>
</string-name> (<year>2011</year>). <article-title>A noise‐reduction GWAS analysis implicates altered regulation of neurite outgrowth and guidance in autism</article-title>. <source xml:lang="en"/>Molecular Autism, <volume>2</volume>(<issue>1</issue>), <fpage>1</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-2-1</pub-id>
<pub-id pub-id-type="pmid">21247446</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0046">
<mixed-citation id="brb3978-cit-0046" publication-type="journal">
<string-name>
<surname>Jacquemont</surname>, <given-names>M. L.</given-names>
</string-name>, <string-name>
<surname>Sanlaville</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Redon</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Raoul</surname>, <given-names>O.</given-names>
</string-name>, <string-name>
<surname>Cormier‐Daire</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Lyonnet</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Philippe</surname>, <given-names>A.</given-names>
</string-name> (<year>2006</year>). <article-title>Array‐based comparative genomic hybridisation identifies high frequency of cryptic chromosomal rearrangements in patients with syndromic autism spectrum disorders</article-title>. <source xml:lang="en"/>Journal of Medical Genetics, <volume>43</volume>(<issue>11</issue>), <fpage>843</fpage>–<lpage>849</lpage>. <pub-id pub-id-type="doi">10.1136/jmg.2006.043166</pub-id>
<pub-id pub-id-type="pmid">16840569</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0047">
<mixed-citation id="brb3978-cit-0047" publication-type="journal">
<string-name>
<surname>Jamain</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Quach</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Betancur</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Rastam</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Colineaux</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Gillberg</surname>, <given-names>I. C.</given-names>
</string-name>, … <collab collab-type="authors">Paris Autism Research International Sibpair Study</collab>
(<year>2003</year>). <article-title>Mutations of the X‐linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>34</volume>(<issue>1</issue>), <fpage>27</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1038/ng1136</pub-id>
<pub-id pub-id-type="pmid">12669065</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0048">
<mixed-citation id="brb3978-cit-0048" publication-type="journal">
<string-name>
<surname>Kaczorowski</surname>, <given-names>G. J.</given-names>
</string-name>, <string-name>
<surname>McManus</surname>, <given-names>O. B.</given-names>
</string-name>, <string-name>
<surname>Priest</surname>, <given-names>B. T.</given-names>
</string-name>, &amp; <string-name>
<surname>Garcia</surname>, <given-names>M. L.</given-names>
</string-name> (<year>2008</year>). <article-title>Ion channels as drug targets: The next GPCRs</article-title>. <source xml:lang="en"/>The Journal of General Physiology, <volume>131</volume>(<issue>5</issue>), <fpage>399</fpage>–<lpage>405</lpage>. <pub-id pub-id-type="doi">10.1085/jgp.200709946</pub-id>
<pub-id pub-id-type="pmid">18411331</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0049">
<mixed-citation id="brb3978-cit-0049" publication-type="journal">
<string-name>
<surname>Kalkman</surname>, <given-names>H. O.</given-names>
</string-name> (<year>2012</year>). <article-title>A review of the evidence for the canonical Wnt pathway in autism spectrum disorders</article-title>. <source xml:lang="en"/>Molecular Autism, <volume>3</volume>(<issue>1</issue>), <fpage>10</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-3-10</pub-id>
<pub-id pub-id-type="pmid">23083465</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0050">
<mixed-citation id="brb3978-cit-0050" publication-type="journal">
<string-name>
<surname>Kang</surname>, <given-names>J. Q.</given-names>
</string-name>, &amp; <string-name>
<surname>Barnes</surname>, <given-names>G.</given-names>
</string-name> (<year>2013</year>). <article-title>A common susceptibility factor of both autism and epilepsy: Functional deficiency of GABA A receptors</article-title>. <source xml:lang="en"/>Journal of Autism and Developmental Disorders, <volume>43</volume>(<issue>1</issue>), <fpage>68</fpage>–<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-012-1543-7</pub-id>
<pub-id pub-id-type="pmid">22555366</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0051">
<mixed-citation id="brb3978-cit-0051" publication-type="journal">
<string-name>
<surname>Kelleher</surname>
<suffix>3rd</suffix>, <given-names>R. J.</given-names>
</string-name>, &amp; <string-name>
<surname>Bear</surname>, <given-names>M. F.</given-names>
</string-name> (<year>2008</year>). <article-title>The autistic neuron: Troubled translation?</article-title>
<source xml:lang="en"/>Cell, <volume>135</volume>(<issue>3</issue>), <fpage>401</fpage>–<lpage>406</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.10.017</pub-id>
<pub-id pub-id-type="pmid">18984149</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0052">
<mixed-citation id="brb3978-cit-0052" publication-type="journal">
<string-name>
<surname>Kim</surname>, <given-names>P. M.</given-names>
</string-name>, <string-name>
<surname>Aizawa</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>P. S.</given-names>
</string-name>, <string-name>
<surname>Huang</surname>, <given-names>A. S.</given-names>
</string-name>, <string-name>
<surname>Wickramasinghe</surname>, <given-names>S. R.</given-names>
</string-name>, <string-name>
<surname>Kashani</surname>, <given-names>A. H.</given-names>
</string-name>, … <string-name>
<surname>Snyder</surname>, <given-names>S. H.</given-names>
</string-name> (<year>2005</year>). <article-title>Serine racemase: Activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration</article-title>. <source xml:lang="en"/>Proceedings of the National Academy of Sciences of the United States of America, <volume>102</volume>(<issue>6</issue>), <fpage>2105</fpage>–<lpage>2110</lpage>. <pub-id pub-id-type="doi">10.1073/pnas.0409723102</pub-id>
<pub-id pub-id-type="pmid">15684087</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0053">
<mixed-citation id="brb3978-cit-0053" publication-type="journal">
<string-name>
<surname>Ko</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Song</surname>, <given-names>D. H.</given-names>
</string-name>, &amp; <string-name>
<surname>Cheon</surname>, <given-names>K. A.</given-names>
</string-name> (<year>2016</year>). <article-title>The effect of epilepsy on autistic symptom severity assessed by the social responsiveness scale in children with autism spectrum disorder</article-title>. <source xml:lang="en"/>Behavioral and Brain Functions, <volume>12</volume>(<issue>1</issue>), <fpage>20</fpage>
<pub-id pub-id-type="doi">10.1186/s12993-016-0105-0</pub-id>
<pub-id pub-id-type="pmid">27350381</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0054">
<mixed-citation id="brb3978-cit-0054" publication-type="journal">
<string-name>
<surname>Krey</surname>, <given-names>J. F.</given-names>
</string-name>, &amp; <string-name>
<surname>Dolmetsch</surname>, <given-names>R. E.</given-names>
</string-name> (<year>2007</year>). <article-title>Molecular mechanisms of autism: A possible role for Ca<sup>2+</sup> signaling</article-title>. <source xml:lang="en"/>Current Opinion in Neurobiology, <volume>17</volume>(<issue>1</issue>), <fpage>112</fpage>–<lpage>119</lpage>. <pub-id pub-id-type="doi">10.1016/j.conb.2007.01.010</pub-id>
<pub-id pub-id-type="pmid">17275285</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0055">
<mixed-citation id="brb3978-cit-0055" publication-type="journal">
<string-name>
<surname>Krumm</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>O'Roak</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Shendure</surname>, <given-names>J.</given-names>
</string-name>, &amp; <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2014</year>). <article-title>A de novo convergence of autism genetics and molecular neuroscience</article-title>. <source xml:lang="en"/>Trends in Neurosciences, <volume>37</volume>(<issue>2</issue>), <fpage>95</fpage>–<lpage>105</lpage>. <pub-id pub-id-type="doi">10.1016/j.tins.2013.11.005</pub-id>
<pub-id pub-id-type="pmid">24387789</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0056">
<mixed-citation id="brb3978-cit-0056" publication-type="journal">
<string-name>
<surname>Kuang</surname>, <given-names>Q.</given-names>
</string-name>, <string-name>
<surname>Purhonen</surname>, <given-names>P.</given-names>
</string-name>, &amp; <string-name>
<surname>Hebert</surname>, <given-names>H.</given-names>
</string-name> (<year>2015</year>). <article-title>Structure of potassium channels</article-title>. <source xml:lang="en"/>Cellular and Molecular Life Sciences, <volume>72</volume>(<issue>19</issue>), <fpage>3677</fpage>–<lpage>3693</lpage>. <pub-id pub-id-type="doi">10.1007/s00018-015-1948-5</pub-id>
<pub-id pub-id-type="pmid">26070303</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0057">
<mixed-citation id="brb3978-cit-0057" publication-type="journal">
<string-name>
<surname>Kyle</surname>, <given-names>D. J.</given-names>
</string-name>, &amp; <string-name>
<surname>Ilyin</surname>, <given-names>V. I.</given-names>
</string-name> (<year>2007</year>). <article-title>Sodium channel blockers</article-title>. <source xml:lang="en"/>Journal of Medicinal Chemistry, <volume>50</volume>(<issue>11</issue>), <fpage>2583</fpage>–<lpage>2588</lpage>. <pub-id pub-id-type="doi">10.1021/jm061005v</pub-id>
<pub-id pub-id-type="pmid">17489575</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0058">
<mixed-citation id="brb3978-cit-0058" publication-type="journal">
<string-name>
<surname>La Malfa</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Lassi</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Bertelli</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Salvini</surname>, <given-names>R.</given-names>
</string-name>, &amp; <string-name>
<surname>Placidi</surname>, <given-names>G. F.</given-names>
</string-name> (<year>2004</year>). <article-title>Autism and intellectual disability: A study of prevalence on a sample of the Italian population</article-title>. <source xml:lang="en"/>Journal of Intellectual Disability Research, <volume>48</volume>(<issue>3</issue>), <fpage>262</fpage>–<lpage>267</lpage>. <pub-id pub-id-type="doi">10.1111/j.1365-2788.2003.00567.x</pub-id>
<pub-id pub-id-type="pmid">15025669</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0059">
<mixed-citation id="brb3978-cit-0059" publication-type="journal">
<string-name>
<surname>Lai</surname>, <given-names>M. C.</given-names>
</string-name>, <string-name>
<surname>Lombardo</surname>, <given-names>M. V.</given-names>
</string-name>, <string-name>
<surname>Auyeung</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Chakrabarti</surname>, <given-names>B.</given-names>
</string-name>, &amp; <string-name>
<surname>Baron‐Cohen</surname>, <given-names>S.</given-names>
</string-name> (<year>2015</year>). <article-title>Sex/gender differences and autism: Setting the scene for future research</article-title>. <source xml:lang="en"/>Journal of the American Academy of Child and Adolescent Psychiatry, <volume>54</volume>(<issue>1</issue>), <fpage>11</fpage>–<lpage>24</lpage>. <pub-id pub-id-type="doi">10.1016/j.jaac.2014.10.003</pub-id>
<pub-id pub-id-type="pmid">25524786</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0060">
<mixed-citation id="brb3978-cit-0060" publication-type="journal">
<string-name>
<surname>Lakhan</surname>, <given-names>S. E.</given-names>
</string-name>, <string-name>
<surname>Caro</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Hadzimichalis</surname>, <given-names>N.</given-names>
</string-name> (<year>2013</year>). <article-title>NMDA receptor activity in neuropsychiatric disorders</article-title>. <source xml:lang="en"/>Frontiers in Psychiatry, <volume>4</volume>, <fpage>52</fpage>.<pub-id pub-id-type="pmid">23772215</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0061">
<mixed-citation id="brb3978-cit-0061" publication-type="journal">
<string-name>
<surname>Laumonnier</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Roger</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Guerin</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Molinari</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>M'Rad</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Cahard</surname>, <given-names>D.</given-names>
</string-name>, … <string-name>
<surname>Briault</surname>, <given-names>S.</given-names>
</string-name> (<year>2006</year>). <article-title>Association of a functional deficit of the BKCa channel, a synaptic regulator of neuronal excitability, with autism and mental retardation</article-title>. <source xml:lang="en"/>The American Journal of Psychiatry, <volume>163</volume>(<issue>9</issue>), <fpage>1622</fpage>–<lpage>1629</lpage>. <pub-id pub-id-type="doi">10.1176/ajp.2006.163.9.1622</pub-id>
<pub-id pub-id-type="pmid">16946189</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0062">
<mixed-citation id="brb3978-cit-0062" publication-type="journal">
<string-name>
<surname>Lee</surname>, <given-names>E. J.</given-names>
</string-name>, <string-name>
<surname>Choi</surname>, <given-names>S. Y.</given-names>
</string-name>, &amp; <string-name>
<surname>Kim</surname>, <given-names>E.</given-names>
</string-name> (<year>2015</year>). <article-title>NMDA receptor dysfunction in autism spectrum disorders</article-title>. <source xml:lang="en"/>Current Opinion in Pharmacology, <volume>20</volume>, <fpage>8</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1016/j.coph.2014.10.007</pub-id>
<pub-id pub-id-type="pmid">25636159</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0063">
<mixed-citation id="brb3978-cit-0063" publication-type="journal">
<string-name>
<surname>Lemonnier</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Degrez</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Phelep</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tyzio</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Josse</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Grandgeorge</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Ben‐Ari</surname>, <given-names>Y.</given-names>
</string-name> (<year>2012</year>). <article-title>A randomised controlled trial of bumetanide in the treatment of autism in children</article-title>. <source xml:lang="en"/>Translational Psychiatry, <volume>2</volume>, <fpage>e202</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2012.124</pub-id>
<pub-id pub-id-type="pmid">23233021</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0064">
<mixed-citation id="brb3978-cit-0064" publication-type="journal">
<string-name>
<surname>Levy</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Ronemus</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yamrom</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>Y.‐H.</given-names>
</string-name>, <string-name>
<surname>Leotta</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kendall</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Wigler</surname>, <given-names>M.</given-names>
</string-name> (<year>2011</year>). <article-title>Rare de novo and transmitted copy‐number variation in autistic spectrum disorders</article-title>. <source xml:lang="en"/>Neuron, <volume>70</volume>(<issue>5</issue>), <fpage>886</fpage>–<lpage>897</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.05.015</pub-id>
<pub-id pub-id-type="pmid">21658582</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0065">
<mixed-citation id="brb3978-cit-0065" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Nguyen</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Gleason</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Lotspeich</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Spiker</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Risch</surname>, <given-names>N.</given-names>
</string-name>, &amp; <string-name>
<surname>Myers</surname>, <given-names>R. M.</given-names>
</string-name> (<year>2004</year>). <article-title>Lack of evidence for an association between WNT2 and RELN polymorphisms and autism</article-title>. <source xml:lang="en"/>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, <volume>126B</volume>(<issue>1</issue>), <fpage>51</fpage>–<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1002/(ISSN)1096-8628</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0066">
<mixed-citation id="brb3978-cit-0066" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>You</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Yue</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Jia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>T.</given-names>
</string-name>, … <string-name>
<surname>Zhang</surname>, <given-names>D.</given-names>
</string-name> (<year>2015</year>). <article-title>Genetic evidence for possible involvement of the calcium channel gene CACNA1A in autism pathogenesis in Chinese Han population</article-title>. <source xml:lang="en"/>PLoS One, <volume>10</volume>(<issue>11</issue>), <fpage>e0142887</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0142887</pub-id>
<pub-id pub-id-type="pmid">26566276</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0067">
<mixed-citation id="brb3978-cit-0067" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>You</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Jia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Yu</surname>, <given-names>H.</given-names>
</string-name>, … <string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name> (<year>2015</year>). <article-title>Schizophrenia related variants in CACNA1C also confer risk of autism</article-title>. <source xml:lang="en"/>PLoS One, <volume>10</volume>(<issue>7</issue>), <fpage>e0133247</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0133247</pub-id>
<pub-id pub-id-type="pmid">26204268</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0068">
<mixed-citation id="brb3978-cit-0068" publication-type="journal">
<string-name>
<surname>Li</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Zou</surname>, <given-names>H.</given-names>
</string-name>, &amp; <string-name>
<surname>Brown</surname>, <given-names>W. T.</given-names>
</string-name> (<year>2012</year>). <article-title>Genes associated with autism spectrum disorder</article-title>. <source xml:lang="en"/>Brain Research Bulletin, <volume>88</volume>(<issue>6</issue>), <fpage>543</fpage>–<lpage>552</lpage>. <pub-id pub-id-type="doi">10.1016/j.brainresbull.2012.05.017</pub-id>
<pub-id pub-id-type="pmid">22688012</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0069">
<mixed-citation id="brb3978-cit-0069" publication-type="journal">
<string-name>
<surname>Liu</surname>, <given-names>X.</given-names>
</string-name>, &amp; <string-name>
<surname>Takumi</surname>, <given-names>T.</given-names>
</string-name> (<year>2014</year>). <article-title>Genomic and genetic aspects of autism spectrum disorder</article-title>. <source xml:lang="en"/>Biochemical and Biophysical Research Communications, <volume>452</volume>(<issue>2</issue>), <fpage>244</fpage>–<lpage>253</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2014.08.108</pub-id>
<pub-id pub-id-type="pmid">25173933</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0070">
<mixed-citation id="brb3978-cit-0070" publication-type="journal">
<string-name>
<surname>Loscher</surname>, <given-names>W.</given-names>
</string-name> (<year>2002</year>). <article-title>Basic pharmacology of valproate: A review after 35 years of clinical use for the treatment of epilepsy</article-title>. <source xml:lang="en"/>CNS Drugs, <volume>16</volume>(<issue>10</issue>), <fpage>669</fpage>–<lpage>694</lpage>. <pub-id pub-id-type="doi">10.2165/00023210-200216100-00003</pub-id>
<pub-id pub-id-type="pmid">12269861</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0071">
<mixed-citation id="brb3978-cit-0071" publication-type="journal">
<string-name>
<surname>Lu</surname>, <given-names>A. T.</given-names>
</string-name>, <string-name>
<surname>Dai</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Martinez‐Agosto</surname>, <given-names>J. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Cantor</surname>, <given-names>R. M.</given-names>
</string-name> (<year>2012</year>). <article-title>Support for calcium channel gene defects in autism spectrum disorders</article-title>. <source xml:lang="en"/>Molecular Autism, <volume>3</volume>(<issue>1</issue>), <fpage>18</fpage>
<pub-id pub-id-type="doi">10.1186/2040-2392-3-18</pub-id>
<pub-id pub-id-type="pmid">23241247</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0072">
<mixed-citation id="brb3978-cit-0072" publication-type="journal">
<string-name>
<surname>Ma</surname>, <given-names>X. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Blenis</surname>, <given-names>J.</given-names>
</string-name> (<year>2009</year>). <article-title>Molecular mechanisms of mTOR‐mediated translational control</article-title>. <source xml:lang="en"/>Nature Reviews Molecular Cell Biology, <volume>10</volume>(<issue>5</issue>), <fpage>307</fpage>–<lpage>318</lpage>. <pub-id pub-id-type="doi">10.1038/nrm2672</pub-id>
<pub-id pub-id-type="pmid">19339977</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0073">
<mixed-citation id="brb3978-cit-0073" publication-type="journal">
<string-name>
<surname>Mabb</surname>, <given-names>A. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Ehlers</surname>, <given-names>M. D.</given-names>
</string-name> (<year>2010</year>). <article-title>Ubiquitination in postsynaptic function and plasticity</article-title>. <source xml:lang="en"/>Annual Review of Cell and Developmental Biology, <volume>26</volume>, <fpage>179</fpage>–<lpage>210</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-cellbio-100109-104129</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0074">
<mixed-citation id="brb3978-cit-0074" publication-type="journal">
<string-name>
<surname>Marshall</surname>, <given-names>C. R.</given-names>
</string-name>, <string-name>
<surname>Noor</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Vincent</surname>, <given-names>J. B.</given-names>
</string-name>, <string-name>
<surname>Lionel</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Feuk</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Skaug</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Scherer</surname>, <given-names>S. W.</given-names>
</string-name> (<year>2008</year>). <article-title>Structural variation of chromosomes in autism spectrum disorder</article-title>. <source xml:lang="en"/>The American Journal of Human Genetics, <volume>82</volume>(<issue>2</issue>), <fpage>477</fpage>–<lpage>488</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2007.12.009</pub-id>
<pub-id pub-id-type="pmid">18252227</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0075">
<mixed-citation id="brb3978-cit-0075" publication-type="journal">
<string-name>
<surname>Martin‐Ruiz</surname>, <given-names>C. M.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Perry</surname>, <given-names>R. H.</given-names>
</string-name>, <string-name>
<surname>Baumann</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Court</surname>, <given-names>J. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Perry</surname>, <given-names>E. K.</given-names>
</string-name> (<year>2004</year>). <article-title>Molecular analysis of nicotinic receptor expression in autism</article-title>. <source xml:lang="en"/>Brain Research Molecular Brain Research, <volume>123</volume>(<issue>1–2</issue>), <fpage>81</fpage>–<lpage>90</lpage>. <pub-id pub-id-type="doi">10.1016/j.molbrainres.2004.01.003</pub-id>
<pub-id pub-id-type="pmid">15046869</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0076">
<mixed-citation id="brb3978-cit-0076" publication-type="journal">
<string-name>
<surname>Matsunami</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Hadley</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Hensel</surname>, <given-names>C. H.</given-names>
</string-name>, <string-name>
<surname>Christensen</surname>, <given-names>G. B.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Frackelton</surname>, <given-names>E.</given-names>
</string-name>, … <string-name>
<surname>Hakonarson</surname>, <given-names>H.</given-names>
</string-name> (<year>2013</year>). <article-title>Identification of rare recurrent copy number variants in high‐risk autism families and their prevalence in a large ASD population</article-title>. <source xml:lang="en"/>PLoS One, <volume>8</volume>(<issue>1</issue>), <fpage>e52239</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0052239</pub-id>
<pub-id pub-id-type="pmid">23341896</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0077">
<mixed-citation id="brb3978-cit-0077" publication-type="journal">
<string-name>
<surname>McBride</surname>, <given-names>K. L.</given-names>
</string-name>, <string-name>
<surname>Varga</surname>, <given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Pastore</surname>, <given-names>M. T.</given-names>
</string-name>, <string-name>
<surname>Prior</surname>, <given-names>T. W.</given-names>
</string-name>, <string-name>
<surname>Manickam</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Atkin</surname>, <given-names>J. F.</given-names>
</string-name>, &amp; <string-name>
<surname>Herman</surname>, <given-names>G. E.</given-names>
</string-name> (<year>2010</year>). <article-title>Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly</article-title>. <source xml:lang="en"/>Autism Research, <volume>3</volume>(<issue>3</issue>), <fpage>137</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1002/aur.132</pub-id>
<pub-id pub-id-type="pmid">20533527</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0078">
<mixed-citation id="brb3978-cit-0078" publication-type="journal">
<string-name>
<surname>Merner</surname>, <given-names>N. D.</given-names>
</string-name>, <string-name>
<surname>Mercado</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Khanna</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<surname>Hodgkinson</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Bruat</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Awadalla</surname>, <given-names>P.</given-names>
</string-name>, … <string-name>
<surname>Kahle</surname>, <given-names>K. T.</given-names>
</string-name> (<year>2016</year>). <article-title>Gain‐of‐function missense variant in SLC12A2, encoding the bumetanide‐sensitive NKCC1 cotransporter, identified in human schizophrenia</article-title>. <source xml:lang="en"/>Journal of Psychiatric Research, <volume>77</volume>, <fpage>22</fpage>–<lpage>26</lpage>. <pub-id pub-id-type="doi">10.1016/j.jpsychires.2016.02.016</pub-id>
<pub-id pub-id-type="pmid">26955005</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0079">
<mixed-citation id="brb3978-cit-0079" publication-type="journal">
<string-name>
<surname>Mony</surname>, <given-names>T. J.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J. W.</given-names>
</string-name>, <string-name>
<surname>Dreyfus</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>DiCicco‐Bloom</surname>, <given-names>E.</given-names>
</string-name>, &amp; <string-name>
<surname>Lee</surname>, <given-names>H. J.</given-names>
</string-name> (<year>2016</year>). <article-title>Valproic acid exposure during early postnatal gliogenesis leads to autistic‐like behaviors in rats</article-title>. <source xml:lang="en"/>Clinical Psychopharmacology and Neuroscience, <volume>14</volume>(<issue>4</issue>), <fpage>338</fpage>–<lpage>344</lpage>. <pub-id pub-id-type="doi">10.9758/cpn.2016.14.4.338</pub-id>
<pub-id pub-id-type="pmid">27776385</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0080">
<mixed-citation id="brb3978-cit-0080" publication-type="journal">
<string-name>
<surname>Moosmang</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Haider</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Klugbauer</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Adelsberger</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Langwieser</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Muller</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Kleppisch</surname>, <given-names>T.</given-names>
</string-name> (<year>2005</year>). <article-title>Role of hippocampal Cav1.2 Ca<sup>2+</sup> channels in NMDA receptor‐independent synaptic plasticity and spatial memory</article-title>. <source xml:lang="en"/>The Journal of Neuroscience, <volume>25</volume>(<issue>43</issue>), <fpage>9883</fpage>–<lpage>9892</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1531-05.2005</pub-id>
<pub-id pub-id-type="pmid">16251435</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0081">
<mixed-citation id="brb3978-cit-0081" publication-type="journal">
<string-name>
<surname>Morrow</surname>, <given-names>E. M.</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>, <given-names>S.‐Y.</given-names>
</string-name>, <string-name>
<surname>Flavell</surname>, <given-names>S. W.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>T.‐K.</given-names>
</string-name>, <string-name>
<surname>Lin</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Hill</surname>, <given-names>R. S.</given-names>
</string-name>, … <string-name>
<surname>Walsh</surname>, <given-names>C. A.</given-names>
</string-name> (<year>2008</year>). <article-title>Identifying autism loci and genes by tracing recent shared ancestry</article-title>. <source xml:lang="en"/>Science, <volume>321</volume>(<issue>5886</issue>), <fpage>218</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.1126/science.1157657</pub-id>
<pub-id pub-id-type="pmid">18621663</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0082">
<mixed-citation id="brb3978-cit-0082" publication-type="journal">
<string-name>
<surname>Napoli</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Mercaldo</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Boyl</surname>, <given-names>P. P.</given-names>
</string-name>, <string-name>
<surname>Eleuteri</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Zalfa</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>De Rubeis</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Bagni</surname>, <given-names>C.</given-names>
</string-name> (<year>2008</year>). <article-title>The fragile X syndrome protein represses activity‐dependent translation through CYFIP1, a new 4E‐BP</article-title>. <source xml:lang="en"/>Cell, <volume>134</volume>(<issue>6</issue>), <fpage>1042</fpage>–<lpage>1054</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2008.07.031</pub-id>
<pub-id pub-id-type="pmid">18805096</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0083">
<mixed-citation id="brb3978-cit-0083" publication-type="journal">
<string-name>
<surname>Neale</surname>, <given-names>B. M.</given-names>
</string-name>, <string-name>
<surname>Kou</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Ma'ayan</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Samocha</surname>, <given-names>K. E.</given-names>
</string-name>, <string-name>
<surname>Sabo</surname>, <given-names>A.</given-names>
</string-name>, … <string-name>
<surname>Daly</surname>, <given-names>M. J.</given-names>
</string-name> (<year>2012</year>). <article-title>Patterns and rates of exonic de novo mutations in autism spectrum disorders</article-title>. <source xml:lang="en"/>Nature, <volume>485</volume>(<issue>7397</issue>), <fpage>242</fpage>–<lpage>245</lpage>. <pub-id pub-id-type="doi">10.1038/nature11011</pub-id>
<pub-id pub-id-type="pmid">22495311</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0084">
<mixed-citation id="brb3978-cit-0084" publication-type="journal">
<string-name>
<surname>O'Roak</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Deriziotis</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Vives</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>, <given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Girirajan</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2011</year>). <article-title>Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>43</volume>(<issue>6</issue>), <fpage>585</fpage>–<lpage>589</lpage>. <pub-id pub-id-type="doi">10.1038/ng.835</pub-id>
<pub-id pub-id-type="pmid">21572417</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0085">
<mixed-citation id="brb3978-cit-0085" publication-type="journal">
<string-name>
<surname>O'Roak</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Vives</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Fu</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Egertson</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Stanaway</surname>, <given-names>I. B.</given-names>
</string-name>, <string-name>
<surname>Phelps</surname>, <given-names>I. G.</given-names>
</string-name>, … <string-name>
<surname>Shendure</surname>, <given-names>J.</given-names>
</string-name> (<year>2012</year>). <article-title>Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders</article-title>. <source xml:lang="en"/>Science, <volume>338</volume>(<issue>6114</issue>), <fpage>1619</fpage>–<lpage>1622</lpage>. <pub-id pub-id-type="doi">10.1126/science.1227764</pub-id>
<pub-id pub-id-type="pmid">23160955</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0086">
<mixed-citation id="brb3978-cit-0086" publication-type="journal">
<string-name>
<surname>O'Roak</surname>, <given-names>B. J.</given-names>
</string-name>, <string-name>
<surname>Vives</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Girirajan</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Karakoc</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Krumm</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Coe</surname>, <given-names>B. P.</given-names>
</string-name>, … <string-name>
<surname>Eichler</surname>, <given-names>E. E.</given-names>
</string-name> (<year>2012</year>). <article-title>Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations</article-title>. <source xml:lang="en"/>Nature, <volume>485</volume>(<issue>7397</issue>), <fpage>246</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1038/nature10989</pub-id>
<pub-id pub-id-type="pmid">22495309</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0087">
<mixed-citation id="brb3978-cit-0087" publication-type="journal">
<string-name>
<surname>Ozonoff</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Young</surname>, <given-names>G. S.</given-names>
</string-name>, <string-name>
<surname>Carter</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Messinger</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Yirmiya</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Zwaigenbaum</surname>, <given-names>L.</given-names>
</string-name>, … <string-name>
<surname>Stone</surname>, <given-names>W. L.</given-names>
</string-name> (<year>2011</year>). <article-title>Recurrence risk for autism spectrum disorders: A Baby Siblings Research Consortium study</article-title>. <source xml:lang="en"/>Pediatrics, <volume>128</volume>(<issue>3</issue>), <fpage>e488</fpage>–<lpage>e495</lpage>.<pub-id pub-id-type="pmid">21844053</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0088">
<mixed-citation id="brb3978-cit-0088" publication-type="journal">
<string-name>
<surname>Parellada</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Penzol</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Pina</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Gonzalez‐Vioque</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Zalsman</surname>, <given-names>G.</given-names>
</string-name>, &amp; <string-name>
<surname>Arango</surname>, <given-names>C.</given-names>
</string-name> (<year>2014</year>). <article-title>The neurobiology of autism spectrum disorders</article-title>. <source xml:lang="en"/>European Psychiatry, <volume>29</volume>(<issue>1</issue>), <fpage>11</fpage>–<lpage>19</lpage>. <pub-id pub-id-type="doi">10.1016/j.eurpsy.2013.02.005</pub-id>
<pub-id pub-id-type="pmid">24275633</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0089">
<mixed-citation id="brb3978-cit-0089" publication-type="journal">
<string-name>
<surname>Park</surname>, <given-names>H. R.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Moon</surname>, <given-names>H. E.</given-names>
</string-name>, <string-name>
<surname>Lee</surname>, <given-names>D. S.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>B. N.</given-names>
</string-name>, <string-name>
<surname>Kim</surname>, <given-names>J.</given-names>
</string-name>, … <string-name>
<surname>Paek</surname>, <given-names>S. H.</given-names>
</string-name> (<year>2016</year>). <article-title>A short review on the current understanding of autism spectrum disorders</article-title>. <source xml:lang="en"/>Experimental Neurobiology, <volume>25</volume>(<issue>1</issue>), <fpage>1</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.5607/en.2016.25.1.1</pub-id>
<pub-id pub-id-type="pmid">26924928</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0090">
<mixed-citation id="brb3978-cit-0090" publication-type="journal">
<string-name>
<surname>Persico</surname>, <given-names>A. M.</given-names>
</string-name>, &amp; <string-name>
<surname>Napolioni</surname>, <given-names>V.</given-names>
</string-name> (<year>2013</year>). <article-title>Autism genetics</article-title>. <source xml:lang="en"/>Behavioural Brain Research, <volume>251</volume>, <fpage>95</fpage>–<lpage>112</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbr.2013.06.012</pub-id>
<pub-id pub-id-type="pmid">23769996</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0091">
<mixed-citation id="brb3978-cit-0091" publication-type="journal">
<string-name>
<surname>Pinggera</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Lieb</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Benedetti</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Lampert</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Monteleone</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Liedl</surname>, <given-names>K. R.</given-names>
</string-name>, … <string-name>
<surname>Striessnig</surname>, <given-names>J.</given-names>
</string-name> (<year>2015</year>). <article-title>CACNA1D de novo mutations in autism spectrum disorders activate Cav1.3L‐type calcium channels</article-title>. <source xml:lang="en"/>Biological Psychiatry, <volume>77</volume>(<issue>9</issue>), <fpage>816</fpage>–<lpage>822</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2014.11.020</pub-id>
<pub-id pub-id-type="pmid">25620733</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0092">
<mixed-citation id="brb3978-cit-0092" publication-type="journal">
<string-name>
<surname>Pinto</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Darvishi</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Shi</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Rajan</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Rigler</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fitzgerald</surname>, <given-names>T.</given-names>
</string-name>, … <string-name>
<surname>Feuk</surname>, <given-names>L.</given-names>
</string-name> (<year>2011</year>). <article-title>Comprehensive assessment of array‐based platforms and calling algorithms for detection of copy number variants</article-title>. <source xml:lang="en"/>Nature Biotechnology, <volume>29</volume>(<issue>6</issue>), <fpage>512</fpage>–<lpage>520</lpage>. <pub-id pub-id-type="doi">10.1038/nbt.1852</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0093">
<mixed-citation id="brb3978-cit-0093" publication-type="journal">
<string-name>
<surname>Pinto</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Pagnamenta</surname>, <given-names>A. T.</given-names>
</string-name>, <string-name>
<surname>Klei</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Anney</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Merico</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Regan</surname>, <given-names>R.</given-names>
</string-name>, … <string-name>
<surname>Betancur</surname>, <given-names>C.</given-names>
</string-name> (<year>2010</year>). <article-title>Functional impact of global rare copy number variation in autism spectrum disorders</article-title>. <source xml:lang="en"/>Nature, <volume>466</volume>(<issue>7304</issue>), <fpage>368</fpage>–<lpage>372</lpage>. <pub-id pub-id-type="doi">10.1038/nature09146</pub-id>
<pub-id pub-id-type="pmid">20531469</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0094">
<mixed-citation id="brb3978-cit-0094" publication-type="journal">
<string-name>
<surname>Posey</surname>, <given-names>D. J.</given-names>
</string-name>, <string-name>
<surname>Kem</surname>, <given-names>D. L.</given-names>
</string-name>, <string-name>
<surname>Swiezy</surname>, <given-names>N. B.</given-names>
</string-name>, <string-name>
<surname>Sweeten</surname>, <given-names>T. L.</given-names>
</string-name>, <string-name>
<surname>Wiegand</surname>, <given-names>R. E.</given-names>
</string-name>, &amp; <string-name>
<surname>McDougle</surname>, <given-names>C. J.</given-names>
</string-name> (<year>2004</year>). <article-title>A pilot study of D‐cycloserine in subjects with autistic disorder</article-title>. <source xml:lang="en"/>The American Journal of Psychiatry, <volume>161</volume>(<issue>11</issue>), <fpage>2115</fpage>–<lpage>2117</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.161.11.2115</pub-id>
<pub-id pub-id-type="pmid">15514414</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0095">
<mixed-citation id="brb3978-cit-0095" publication-type="journal">
<string-name>
<surname>Robert</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pasquier</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Cohen</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Fradin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Canitano</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Damaj</surname>, <given-names>L.</given-names>
</string-name>, … <string-name>
<surname>Tordjman</surname>, <given-names>S.</given-names>
</string-name> (<year>2017</year>). <article-title>Role of genetics in the etiology of autistic spectrum disorder: Towards a hierarchical diagnostic strategy</article-title>. <source xml:lang="en"/>International Journal of Molecular Sciences, <volume>18</volume>(<issue>3</issue>), <fpage>E618</fpage>
<pub-id pub-id-type="doi">10.3390/ijms18030618</pub-id>
<pub-id pub-id-type="pmid">28287497</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0096">
<mixed-citation id="brb3978-cit-0096" publication-type="journal">
<string-name>
<surname>Roberts</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Tonnsen</surname>, <given-names>B. L.</given-names>
</string-name>, <string-name>
<surname>McCary</surname>, <given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Caravella</surname>, <given-names>K. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Shinkareva</surname>, <given-names>S. V.</given-names>
</string-name> (<year>2016</year>). <article-title>Brief report: Autism symptoms in infants with fragile X syndrome</article-title>. <source xml:lang="en"/>Journal of Autism and Developmental Disorders, <volume>46</volume>, <fpage>3830</fpage>–<lpage>3837</lpage>. <pub-id pub-id-type="doi">10.1007/s10803-016-2903-5</pub-id>
<pub-id pub-id-type="pmid">27628938</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0097">
<mixed-citation id="brb3978-cit-0097" publication-type="book">
<string-name>
<surname>Ronald</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Hoekstra</surname>, <given-names>R.</given-names>
</string-name> (<year>2014</year>). <chapter-title>Progress in understanding the causes of autism spectrum disorders and autistic traits: Twin studies from 1977 to the present day</chapter-title> In <person-group person-group-type="editor"><name><surname>Rhee</surname><given-names>S. H.</given-names></name></person-group>, &amp; <person-group person-group-type="editor"><name><surname>Ronald</surname><given-names>A.</given-names></name></person-group> (Eds.), <source xml:lang="en"/>Behavior genetics of psychopathology (pp. <fpage>33</fpage>–<lpage>65</lpage>). <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer</publisher-name>
<pub-id pub-id-type="doi">10.1007/978-1-4614-9509-3</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0098">
<mixed-citation id="brb3978-cit-0098" publication-type="journal">
<string-name>
<surname>Ronemus</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Iossifov</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Levy</surname>, <given-names>D.</given-names>
</string-name>, &amp; <string-name>
<surname>Wigler</surname>, <given-names>M.</given-names>
</string-name> (<year>2014</year>). <article-title>The role of de novo mutations in the genetics of autism spectrum disorders</article-title>. <source xml:lang="en"/>Nature Reviews Genetics, <volume>15</volume>(<issue>2</issue>), <fpage>133</fpage>–<lpage>141</lpage>. <pub-id pub-id-type="doi">10.1038/nrg3585</pub-id>
</mixed-citation>
</ref>
<ref id="brb3978-bib-0099">
<mixed-citation id="brb3978-cit-0099" publication-type="journal">
<string-name>
<surname>Rose</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Jin</surname>, <given-names>S. X.</given-names>
</string-name>, &amp; <string-name>
<surname>Craig</surname>, <given-names>A. M.</given-names>
</string-name> (<year>2009</year>). <article-title>Heterosynaptic molecular dynamics: Locally induced propagating synaptic accumulation of CaM kinase II</article-title>. <source xml:lang="en"/>Neuron, <volume>61</volume>(<issue>3</issue>), <fpage>351</fpage>–<lpage>358</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2008.12.030</pub-id>
<pub-id pub-id-type="pmid">19217373</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0100">
<mixed-citation id="brb3978-cit-0100" publication-type="journal">
<string-name>
<surname>Rosenberg</surname>, <given-names>R. E.</given-names>
</string-name>, <string-name>
<surname>Law</surname>, <given-names>J. K.</given-names>
</string-name>, <string-name>
<surname>Yenokyan</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>McGready</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Kaufmann</surname>, <given-names>W. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Law</surname>, <given-names>P. A.</given-names>
</string-name> (<year>2009</year>). <article-title>Characteristics and concordance of autism spectrum disorders among 277 twin pairs</article-title>. <source xml:lang="en"/>Archives of Pediatrics &amp; Adolescent Medicine, <volume>163</volume>(<issue>10</issue>), <fpage>907</fpage>–<lpage>914</lpage>. <pub-id pub-id-type="doi">10.1001/archpediatrics.2009.98</pub-id>
<pub-id pub-id-type="pmid">19805709</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0101">
<mixed-citation id="brb3978-cit-0101" publication-type="journal">
<string-name>
<surname>Sanders</surname>, <given-names>S. J.</given-names>
</string-name>, <string-name>
<surname>Murtha</surname>, <given-names>M. T.</given-names>
</string-name>, <string-name>
<surname>Gupta</surname>, <given-names>A. R.</given-names>
</string-name>, <string-name>
<surname>Murdoch</surname>, <given-names>J. D.</given-names>
</string-name>, <string-name>
<surname>Raubeson</surname>, <given-names>M. J.</given-names>
</string-name>, <string-name>
<surname>Willsey</surname>, <given-names>A. J.</given-names>
</string-name>, … <string-name>
<surname>State</surname>, <given-names>M. W.</given-names>
</string-name> (<year>2012</year>). <article-title>De novo mutations revealed by whole‐exome sequencing are strongly associated with autism</article-title>. <source xml:lang="en"/>Nature, <volume>485</volume>(<issue>7397</issue>), <fpage>237</fpage>–<lpage>241</lpage>. <pub-id pub-id-type="doi">10.1038/nature10945</pub-id>
<pub-id pub-id-type="pmid">22495306</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0102">
<mixed-citation id="brb3978-cit-0102" publication-type="journal">
<string-name>
<surname>Sanders Stephan</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Ercan‐Sencicek</surname>, <given-names>A. G.</given-names>
</string-name>, <string-name>
<surname>Hus</surname>, <given-names>V.</given-names>
</string-name>, <string-name>
<surname>Luo</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Murtha Michael</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Moreno‐De‐Luca</surname>, <given-names>D.</given-names>
</string-name>, … <string-name>
<surname>State</surname>, <given-names>M. W.</given-names>
</string-name> (<year>2011</year>). <article-title>Multiple recurrent de novo CNVs, including duplications of the 7q11.23 Williams syndrome region, are strongly associated with autism</article-title>. <source xml:lang="en"/>Neuron, <volume>70</volume>(<issue>5</issue>), <fpage>863</fpage>–<lpage>885</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2011.05.002</pub-id>
<pub-id pub-id-type="pmid">21658581</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0103">
<mixed-citation id="brb3978-cit-0103" publication-type="journal">
<string-name>
<surname>Santini</surname>, <given-names>A. C.</given-names>
</string-name>, <string-name>
<surname>Pierantoni</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Gerlini</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Iorio</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Olabinjo</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Giovane</surname>, <given-names>A.</given-names>
</string-name>, … <string-name>
<surname>Sogos</surname>, <given-names>C.</given-names>
</string-name> (<year>2014</year>). <article-title>Glix 13, a new drug acting on glutamatergic pathways in children and animal models of autism spectrum disorders</article-title>. <source xml:lang="en"/>BioMed Research International, <volume>2014</volume>, <fpage>234295</fpage>.<pub-id pub-id-type="pmid">24605324</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0104">
<mixed-citation id="brb3978-cit-0104" publication-type="journal">
<string-name>
<surname>Sanua</surname>, <given-names>V. D.</given-names>
</string-name> (<year>1983</year>). <article-title>Infantile autism and childhood schizophrenia: Review of the issues from the sociocultural point of view</article-title>. <source xml:lang="en"/>Social Science &amp; Medicine, <volume>17</volume>(<issue>21</issue>), <fpage>1633</fpage>–<lpage>1651</lpage>. <pub-id pub-id-type="doi">10.1016/0277-9536(83)90309-X</pub-id>
<pub-id pub-id-type="pmid">6359455</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0105">
<mixed-citation id="brb3978-cit-0105" publication-type="journal">
<string-name>
<surname>Schratt</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Nigh</surname>, <given-names>E. A.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>W. G.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>L.</given-names>
</string-name>, &amp; <string-name>
<surname>Greenberg</surname>, <given-names>M. E.</given-names>
</string-name> (<year>2004</year>). <article-title>BDNF regulates the translation of a select group of mRNAs by a mammalian target of rapamycin‐phosphatidylinositol 3‐kinase‐dependent pathway during neuronal development</article-title>. <source xml:lang="en"/>The Journal of Neuroscience, <volume>24</volume>(<issue>33</issue>), <fpage>7366</fpage>–<lpage>7377</lpage>. <pub-id pub-id-type="doi">10.1523/JNEUROSCI.1739-04.2004</pub-id>
<pub-id pub-id-type="pmid">15317862</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0106">
<mixed-citation id="brb3978-cit-0106" publication-type="journal">
<string-name>
<surname>Sebat</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lakshmi</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Malhotra</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Troge</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Lese‐Martin</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Walsh</surname>, <given-names>T.</given-names>
</string-name>, … <string-name>
<surname>Wigler</surname>, <given-names>M.</given-names>
</string-name> (<year>2007</year>). <article-title>Strong association of de novo copy number mutations with autism</article-title>. <source xml:lang="en"/>Science, <volume>316</volume>(<issue>5823</issue>), <fpage>445</fpage>–<lpage>449</lpage>. <pub-id pub-id-type="doi">10.1126/science.1138659</pub-id>
<pub-id pub-id-type="pmid">17363630</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0107">
<mixed-citation id="brb3978-cit-0107" publication-type="journal">
<string-name>
<surname>Simms</surname>, <given-names>B. A.</given-names>
</string-name>, &amp; <string-name>
<surname>Zamponi</surname>, <given-names>G. W.</given-names>
</string-name> (<year>2014</year>). <article-title>Neuronal voltage‐gated calcium channels: Structure, function, and dysfunction</article-title>. <source xml:lang="en"/>Neuron, <volume>82</volume>(<issue>1</issue>), <fpage>24</fpage>–<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.neuron.2014.03.016</pub-id>
<pub-id pub-id-type="pmid">24698266</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0108">
<mixed-citation id="brb3978-cit-0108" publication-type="journal">
<string-name>
<surname>Skafidas</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Testa</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Zantomio</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Chana</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Everall</surname>, <given-names>I. P.</given-names>
</string-name>, &amp; <string-name>
<surname>Pantelis</surname>, <given-names>C.</given-names>
</string-name> (<year>2014</year>). <article-title>Predicting the diagnosis of autism spectrum disorder using gene pathway analysis</article-title>. <source xml:lang="en"/>Molecular Psychiatry, <volume>19</volume>(<issue>4</issue>), <fpage>504</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2012.126</pub-id>
<pub-id pub-id-type="pmid">22965006</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0109">
<mixed-citation id="brb3978-cit-0109" publication-type="journal">
<string-name>
<surname>Smith</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Flodman</surname>, <given-names>P. L.</given-names>
</string-name>, <string-name>
<surname>Gargus</surname>, <given-names>J. J.</given-names>
</string-name>, <string-name>
<surname>Simon</surname>, <given-names>M. T.</given-names>
</string-name>, <string-name>
<surname>Verrell</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Haas</surname>, <given-names>R.</given-names>
</string-name>, … <string-name>
<surname>Wallace</surname>, <given-names>D. C.</given-names>
</string-name> (<year>2012</year>). <article-title>Mitochondrial and ion channel gene alterations in autism</article-title>. <source xml:lang="en"/>Biochimica et Biophysica Acta, <volume>1817</volume>(<issue>10</issue>), <fpage>1796</fpage>–<lpage>1802</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbabio.2012.04.004</pub-id>
<pub-id pub-id-type="pmid">22538295</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0110">
<mixed-citation id="brb3978-cit-0110" publication-type="journal">
<string-name>
<surname>Splawski</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Timothy</surname>, <given-names>K. W.</given-names>
</string-name>, <string-name>
<surname>Sharpe</surname>, <given-names>L. M.</given-names>
</string-name>, <string-name>
<surname>Decher</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Bloise</surname>, <given-names>R.</given-names>
</string-name>, … <string-name>
<surname>Keating</surname>, <given-names>M. T.</given-names>
</string-name> (<year>2004</year>). <article-title>Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism</article-title>. <source xml:lang="en"/>Cell, <volume>119</volume>(<issue>1</issue>), <fpage>19</fpage>–<lpage>31</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2004.09.011</pub-id>
<pub-id pub-id-type="pmid">15454078</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0111">
<mixed-citation id="brb3978-cit-0111" publication-type="journal">
<string-name>
<surname>Splawski</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>, <given-names>D. S.</given-names>
</string-name>, <string-name>
<surname>Stotz</surname>, <given-names>S. C.</given-names>
</string-name>, <string-name>
<surname>Cherry</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Clapham</surname>, <given-names>D. E.</given-names>
</string-name>, &amp; <string-name>
<surname>Keating</surname>, <given-names>M. T.</given-names>
</string-name> (<year>2006</year>). <article-title>CACNA1H mutations in autism spectrum disorders</article-title>. <source xml:lang="en"/>The Journal of Biological Chemistry, <volume>281</volume>(<issue>31</issue>), <fpage>22085</fpage>–<lpage>22091</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M603316200</pub-id>
<pub-id pub-id-type="pmid">16754686</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0112">
<mixed-citation id="brb3978-cit-0112" publication-type="journal">
<string-name>
<surname>Srivastava</surname>, <given-names>R. K.</given-names>
</string-name>, <string-name>
<surname>Agarwal</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Pundhir</surname>, <given-names>A.</given-names>
</string-name> (<year>2011</year>). <article-title>Role of donepezil in autism: Its conduciveness in psychopharmacotherapy</article-title>. <source xml:lang="en"/>Case Reports in Psychiatry, <volume>2011</volume>, <fpage>563204</fpage>.<pub-id pub-id-type="pmid">22937405</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0113">
<mixed-citation id="brb3978-cit-0113" publication-type="journal">
<string-name>
<surname>Stary</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kudrnac</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Beyl</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>Hohaus</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Timin</surname>, <given-names>E. N.</given-names>
</string-name>, <string-name>
<surname>Wolschann</surname>, <given-names>P.</given-names>
</string-name>, … <string-name>
<surname>Hering</surname>, <given-names>S.</given-names>
</string-name> (<year>2008</year>). <article-title>Molecular dynamics and mutational analysis of a channelopathy mutation in the IIS6 helix of Ca V 1.2</article-title>. <source xml:lang="en"/>Channels (Austin), <volume>2</volume>(<issue>3</issue>), <fpage>216</fpage>–<lpage>223</lpage>. <pub-id pub-id-type="doi">10.4161/chan.2.3.6160</pub-id>
<pub-id pub-id-type="pmid">18836301</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0114">
<mixed-citation id="brb3978-cit-0114" publication-type="journal">
<string-name>
<surname>Szatmari</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Jones</surname>, <given-names>M. B.</given-names>
</string-name>, <string-name>
<surname>Zwaigenbaum</surname>, <given-names>L.</given-names>
</string-name>, &amp; <string-name>
<surname>MacLean</surname>, <given-names>J. E.</given-names>
</string-name> (<year>1998</year>). <article-title>Genetics of autism: Overview and new directions</article-title>. <source xml:lang="en"/>Journal of Autism and Developmental Disorders, <volume>28</volume>(<issue>5</issue>), <fpage>351</fpage>–<lpage>368</lpage>. <pub-id pub-id-type="doi">10.1023/A:1026096203946</pub-id>
<pub-id pub-id-type="pmid">9813773</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0115">
<mixed-citation id="brb3978-cit-0115" publication-type="journal">
<string-name>
<surname>Tavassoli</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Kolevzon</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>A. T.</given-names>
</string-name>, <string-name>
<surname>Curchack‐Lichtin</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Halpern</surname>, <given-names>D.</given-names>
</string-name>, <string-name>
<surname>Schwartz</surname>, <given-names>L.</given-names>
</string-name>, … <string-name>
<surname>Buxbaum</surname>, <given-names>J. D.</given-names>
</string-name> (<year>2014</year>). <article-title>De novo SCN2A splice site mutation in a boy with Autism spectrum disorder</article-title>. <source xml:lang="en"/>BMC Medical Genetics, <volume>15</volume>, <fpage>35</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2350-15-35</pub-id>
<pub-id pub-id-type="pmid">24650168</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0116">
<mixed-citation id="brb3978-cit-0116" publication-type="journal">
<string-name>
<surname>Toma</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Hervas</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Torrico</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Balmana</surname>, <given-names>N.</given-names>
</string-name>, <string-name>
<surname>Salgado</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Maristany</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Cormand</surname>, <given-names>B.</given-names>
</string-name> (<year>2013</year>). <article-title>Analysis of two language‐related genes in autism: A case‐control association study of FOXP2 and CNTNAP2</article-title>. <source xml:lang="en"/>Psychiatric Genetics, <volume>23</volume>(<issue>2</issue>), <fpage>82</fpage>–<lpage>85</lpage>. <pub-id pub-id-type="doi">10.1097/YPG.0b013e32835d6fc6</pub-id>
<pub-id pub-id-type="pmid">23277129</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0117">
<mixed-citation id="brb3978-cit-0117" publication-type="journal">
<string-name>
<surname>Tremont‐Lukats</surname>, <given-names>I. W.</given-names>
</string-name>, <string-name>
<surname>Megeff</surname>, <given-names>C.</given-names>
</string-name>, &amp; <string-name>
<surname>Backonja</surname>, <given-names>M. M.</given-names>
</string-name> (<year>2000</year>). <article-title>Anticonvulsants for neuropathic pain syndromes: Mechanisms of action and place in therapy</article-title>. <source xml:lang="en"/>Drugs, <volume>60</volume>(<issue>5</issue>), <fpage>1029</fpage>–<lpage>1052</lpage>. <pub-id pub-id-type="doi">10.2165/00003495-200060050-00005</pub-id>
<pub-id pub-id-type="pmid">11129121</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0118">
<mixed-citation id="brb3978-cit-0118" publication-type="journal">
<string-name>
<surname>Uddin</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Tammimies</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Pellecchia</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Alipanahi</surname>, <given-names>B.</given-names>
</string-name>, <string-name>
<surname>Hu</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>Z.</given-names>
</string-name>, … <string-name>
<surname>Scherer</surname>, <given-names>S. W.</given-names>
</string-name> (<year>2014</year>). <article-title>Brain‐expressed exons under purifying selection are enriched for de novo mutations in autism spectrum disorder</article-title>. <source xml:lang="en"/>Nature Genetics, <volume>46</volume>(<issue>7</issue>), <fpage>742</fpage>–<lpage>747</lpage>. <pub-id pub-id-type="doi">10.1038/ng.2980</pub-id>
<pub-id pub-id-type="pmid">24859339</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0119">
<mixed-citation id="brb3978-cit-0119" publication-type="journal">
<string-name>
<surname>Urbano</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Okwara</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Manser</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>, <given-names>K.</given-names>
</string-name>, <string-name>
<surname>Herndon</surname>, <given-names>A.</given-names>
</string-name>, &amp; <string-name>
<surname>Deutsch</surname>, <given-names>S. I.</given-names>
</string-name> (<year>2014</year>). <article-title>A trial of D‐cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder</article-title>. <source xml:lang="en"/>Clinical Neuropharmacology, <volume>37</volume>(<issue>3</issue>), <fpage>69</fpage>–<lpage>72</lpage>. <pub-id pub-id-type="doi">10.1097/WNF.0000000000000033</pub-id>
<pub-id pub-id-type="pmid">24824660</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0120">
<mixed-citation id="brb3978-cit-0120" publication-type="journal">
<string-name>
<surname>van Woerden</surname>, <given-names>G. M.</given-names>
</string-name>, <string-name>
<surname>Harris</surname>, <given-names>K. D.</given-names>
</string-name>, <string-name>
<surname>Hojjati</surname>, <given-names>M. R.</given-names>
</string-name>, <string-name>
<surname>Gustin</surname>, <given-names>R. M.</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>, <given-names>S.</given-names>
</string-name>, <string-name>
<surname>de Avila</surname>, <given-names>Freire. R.</given-names>
</string-name>, … <string-name>
<surname>Weeber</surname>, <given-names>E. J.</given-names>
</string-name> (<year>2007</year>). <article-title>Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of alphaCaMKII inhibitory phosphorylation</article-title>. <source xml:lang="en"/>Nature Neuroscience, <volume>10</volume>(<issue>3</issue>), <fpage>280</fpage>–<lpage>282</lpage>. <pub-id pub-id-type="doi">10.1038/nn1845</pub-id>
<pub-id pub-id-type="pmid">17259980</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0121">
<mixed-citation id="brb3978-cit-0121" publication-type="book">
<string-name>
<surname>Vandam</surname>, <given-names>L. D.</given-names>
</string-name> (<year>1987</year>). <chapter-title>Some aspects of the history of local anesthesia</chapter-title> In <person-group person-group-type="editor"><name><surname>Strichartz</surname><given-names>G. R.</given-names></name></person-group> (Ed.), <source xml:lang="en"/>Local anesthetics (pp. <fpage>1</fpage>–<lpage>19</lpage>). <publisher-loc>Berlin, Heidelberg, Germany</publisher-loc>: <publisher-name>Springer</publisher-name>.</mixed-citation>
</ref>
<ref id="brb3978-bib-0122">
<mixed-citation id="brb3978-cit-0122" publication-type="journal">
<string-name>
<surname>Veeramah</surname>, <given-names>K. R.</given-names>
</string-name>, <string-name>
<surname>O'Brien</surname>, <given-names>J. E.</given-names>
</string-name>, <string-name>
<surname>Meisler</surname>, <given-names>M. H.</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Dib‐Hajj</surname>, <given-names>S. D.</given-names>
</string-name>, <string-name>
<surname>Waxman</surname>, <given-names>S. G.</given-names>
</string-name>, … <string-name>
<surname>Hammer</surname>, <given-names>M. F.</given-names>
</string-name> (<year>2012</year>). <article-title>De novo pathogenic SCN8A mutation identified by whole‐genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP</article-title>. <source xml:lang="en"/>American Journal of Human Genetics, <volume>90</volume>(<issue>3</issue>), <fpage>502</fpage>–<lpage>510</lpage>. <pub-id pub-id-type="doi">10.1016/j.ajhg.2012.01.006</pub-id>
<pub-id pub-id-type="pmid">22365152</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0123">
<mixed-citation id="brb3978-cit-0123" publication-type="journal">
<string-name>
<surname>Voineagu</surname>, <given-names>I.</given-names>
</string-name>, <string-name>
<surname>Wang</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Lowe</surname>, <given-names>J. K.</given-names>
</string-name>, <string-name>
<surname>Tian</surname>, <given-names>Y.</given-names>
</string-name>, <string-name>
<surname>Horvath</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Geschwind</surname>, <given-names>D. H.</given-names>
</string-name> (<year>2011</year>). <article-title>Transcriptomic analysis of autistic brain reveals convergent molecular pathology</article-title>. <source xml:lang="en"/>Nature, <volume>474</volume>(<issue>7351</issue>), <fpage>380</fpage>–<lpage>384</lpage>. <pub-id pub-id-type="doi">10.1038/nature10110</pub-id>
<pub-id pub-id-type="pmid">21614001</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0124">
<mixed-citation id="brb3978-cit-0124" publication-type="journal">
<string-name>
<surname>Vorstman</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Staal</surname>, <given-names>W. G.</given-names>
</string-name>, <string-name>
<surname>van Daalen</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>van Engeland</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Hochstenbach</surname>, <given-names>P. F.</given-names>
</string-name>, &amp; <string-name>
<surname>Franke</surname>, <given-names>L.</given-names>
</string-name> (<year>2006</year>). <article-title>Identification of novel autism candidate regions through analysis of reported cytogenetic abnormalities associated with autism</article-title>. <source xml:lang="en"/>Molecular Psychiatry, <volume>11</volume>(<issue>1</issue>), <fpage>1</fpage>, 18–28. <pub-id pub-id-type="doi">10.1038/sj.mp.4001781</pub-id>
<pub-id pub-id-type="pmid">16205736</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0125">
<mixed-citation id="brb3978-cit-0125" publication-type="journal">
<string-name>
<surname>Waltes</surname>, <given-names>R.</given-names>
</string-name>, <string-name>
<surname>Duketis</surname>, <given-names>E.</given-names>
</string-name>, <string-name>
<surname>Knapp</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Anney</surname>, <given-names>R. J.</given-names>
</string-name>, <string-name>
<surname>Huguet</surname>, <given-names>G.</given-names>
</string-name>, <string-name>
<surname>Schlitt</surname>, <given-names>S.</given-names>
</string-name>, … <string-name>
<surname>Chiocchetti</surname>, <given-names>A. G.</given-names>
</string-name> (<year>2014</year>). <article-title>Common variants in genes of the postsynaptic FMRP signalling pathway are risk factors for autism spectrum disorders</article-title>. <source xml:lang="en"/>Human Genetics, <volume>133</volume>(<issue>6</issue>), <fpage>781</fpage>–<lpage>792</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-013-1416-y</pub-id>
<pub-id pub-id-type="pmid">24442360</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0126">
<mixed-citation id="brb3978-cit-0126" publication-type="journal">
<string-name>
<surname>Weiss</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Arking</surname>, <given-names>D. E.</given-names>
</string-name>, <collab collab-type="authors">The Gene Discovery Project of Johns Hopkins the Autism C</collab>
(<year>2009</year>). <article-title>A genome‐wide linkage and association scan reveals novel loci for autism</article-title>. <source xml:lang="en"/>Nature, <volume>461</volume>(<issue>7265</issue>), <fpage>802</fpage>–<lpage>808</lpage>. <pub-id pub-id-type="doi">10.1038/nature08490</pub-id>
<pub-id pub-id-type="pmid">19812673</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0127">
<mixed-citation id="brb3978-cit-0127" publication-type="journal">
<string-name>
<surname>Weiss</surname>, <given-names>L. A.</given-names>
</string-name>, <string-name>
<surname>Escayg</surname>, <given-names>A.</given-names>
</string-name>, <string-name>
<surname>Kearney</surname>, <given-names>J. A.</given-names>
</string-name>, <string-name>
<surname>Trudeau</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>MacDonald</surname>, <given-names>B. T.</given-names>
</string-name>, <string-name>
<surname>Mori</surname>, <given-names>M.</given-names>
</string-name>, … <string-name>
<surname>Meisler</surname>, <given-names>M. H.</given-names>
</string-name> (<year>2003</year>). <article-title>Sodium channels SCN1A, SCN2A and SCN3A in familial autism</article-title>. <source xml:lang="en"/>Molecular Psychiatry, <volume>8</volume>(<issue>2</issue>), <fpage>186</fpage>–<lpage>194</lpage>. <pub-id pub-id-type="doi">10.1038/sj.mp.4001241</pub-id>
<pub-id pub-id-type="pmid">12610651</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0128">
<mixed-citation id="brb3978-cit-0128" publication-type="journal">
<string-name>
<surname>Yang</surname>, <given-names>W.</given-names>
</string-name>, <string-name>
<surname>Liu</surname>, <given-names>J.</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Jia</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>, <given-names>L.</given-names>
</string-name>, <string-name>
<surname>Lu</surname>, <given-names>T.</given-names>
</string-name>, &amp; <string-name>
<surname>Wang</surname>, <given-names>L.</given-names>
</string-name> (<year>2013</year>). <article-title>The evidence for association of ATP2B2 polymorphisms with autism in Chinese Han population</article-title>. <source xml:lang="en"/>PLoS One, <volume>8</volume>(<issue>4</issue>), <fpage>e61021</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061021</pub-id>
<pub-id pub-id-type="pmid">23620727</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0129">
<mixed-citation id="brb3978-cit-0129" publication-type="journal">
<string-name>
<surname>Yatsenko</surname>, <given-names>S. A.</given-names>
</string-name>, <string-name>
<surname>Hixson</surname>, <given-names>P.</given-names>
</string-name>, <string-name>
<surname>Roney</surname>, <given-names>E. K.</given-names>
</string-name>, <string-name>
<surname>Scott</surname>, <given-names>D. A.</given-names>
</string-name>, <string-name>
<surname>Schaaf</surname>, <given-names>C. P.</given-names>
</string-name>, <string-name>
<surname>Ng</surname>, <given-names>Y. T.</given-names>
</string-name>, … <string-name>
<surname>Lupski</surname>, <given-names>J. R.</given-names>
</string-name> (<year>2012</year>). <article-title>Human subtelomeric copy number gains suggest a DNA replication mechanism for formation: Beyond breakage‐fusion‐bridge for telomere stabilization</article-title>. <source xml:lang="en"/>Human Genetics, <volume>131</volume>(<issue>12</issue>), <fpage>1895</fpage>–<lpage>1910</lpage>. <pub-id pub-id-type="doi">10.1007/s00439-012-1216-9</pub-id>
<pub-id pub-id-type="pmid">22890305</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0130">
<mixed-citation id="brb3978-cit-0130" publication-type="journal">
<string-name>
<surname>Yi</surname>, <given-names>F.</given-names>
</string-name>, <string-name>
<surname>Danko</surname>, <given-names>T.</given-names>
</string-name>, <string-name>
<surname>Botelho</surname>, <given-names>S. C.</given-names>
</string-name>, <string-name>
<surname>Patzke</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Pak</surname>, <given-names>C.</given-names>
</string-name>, <string-name>
<surname>Wernig</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Südhof</surname>, <given-names>T. C.</given-names>
</string-name> (<year>2016</year>). <article-title>Autism‐associated SHANK3 haploinsufficiency causes Ih channelopathy in human neurons</article-title>. <source xml:lang="en"/>Science, <volume>352</volume>(<issue>6286</issue>), <fpage>aaf2669</fpage>
<pub-id pub-id-type="doi">10.1126/science.aaf2669</pub-id>
<pub-id pub-id-type="pmid">26966193</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0131">
<mixed-citation id="brb3978-cit-0131" publication-type="journal">
<string-name>
<surname>Zamponi</surname>, <given-names>G. W.</given-names>
</string-name> (<year>2016</year>). <article-title>Targeting voltage‐gated calcium channels in neurological and psychiatric diseases</article-title>. <source xml:lang="en"/>Nature Reviews Drug Discovery, <volume>15</volume>(<issue>1</issue>), <fpage>19</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1038/nrd.2015.5</pub-id>
<pub-id pub-id-type="pmid">26542451</pub-id></mixed-citation>
</ref>
<ref id="brb3978-bib-0132">
<mixed-citation id="brb3978-cit-0132" publication-type="journal">
<string-name>
<surname>Zhu</surname>, <given-names>M.</given-names>
</string-name>, <string-name>
<surname>Sun</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Chen</surname>, <given-names>X.</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>, <given-names>H.</given-names>
</string-name>, <string-name>
<surname>Duan</surname>, <given-names>M.</given-names>
</string-name>, &amp; <string-name>
<surname>Xu</surname>, <given-names>J.</given-names>
</string-name> (<year>2017</year>). <article-title>Impact of gabapentin on neuronal high voltage‐activated Ca<sup>2+</sup> channel properties of injured‐side axotomized and adjacent uninjured dorsal root ganglions in a rat model of spinal nerve ligation</article-title>. <source xml:lang="en"/>Experimental and Therapeutic Medicine, <volume>13</volume>(<issue>3</issue>), <fpage>851</fpage>–<lpage>860</lpage>. <pub-id pub-id-type="doi">10.3892/etm.2017.4071</pub-id>
<pub-id pub-id-type="pmid">28450909</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>